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Recent studies have suggested a key role of activities related to target genes of transcription fac-
tors (TFs) in cancer signaling pathways. Molecular pathway curation includes mostly upstream
signals which are well-established in the literature, but the activities that are downstream of
TFs are not well understood. The purpose of this thesis is to design a computational method
for exploring TF target genes in a given molecular pathway. We then use this data to stratify
patients and relate TF activity to patient survival.
Transcriptome data can provide a detailed readout of events taking place within a cancer, but
new computational tools are needed to extract maximal biological insights from this data. The
“BioTarget” pipeline incorporates ChIP-seq data into cellular pathway analysis to infer TF ac-
tivity from RNA-seq data. More specifically, it relates the expression of TF target genes (based
on ChIP-seq data) with the status of upstream signaling components to quantify context-specific
TF activity. This mining tool also allowed us to stratify TF binding with activated or suppressed
states of these targets. Two case studies were analyzed utilizing the BioTarget pipeline.
Tham Hong Hoang
University of Connecticut, 2018
First, we evaluated the Th1 and Th2 responses in cancers based on TBX21 and GATA3 path-
way activity, respectively. Low Th1/Th2 activity ratios were associated with poorer survival of
stomach and breast cancer patients, whereas an unbalanced Th1/Th2 response correlated with
a poorer survival of colon cancer patients. Applying our computational tool to the BCL6 TF, a
TF with a lesser-known influence on solid cancers, we found patients with higher BCL6 activity
had significantly improved survival.
Second, we explored target genes of TFs in three molecular pathways of cell proliferation
(TCF7, TCF7L2 and LEF1 in Wnt; MYC, JUN and FOS in Mapk; STAT3 in IGF). These
TFs have well-established roles in cell proliferation and immunosuppression. We used BioTar-
get to explore the oncogenic functions of these TFs by identifying their target genes in specific
cancer types. We discovered that the functions of these TFs were dominantly activated in cer-
tain cancer cohorts. The results of two case studies provided new insight into pathway signals
of cell proliferation and cell differentiation in cancer.
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The objective of this research is to address problems in the multi-disciplinary field of compu-
tational biology and bioinformatics, especially in pathway analysis and data integration tools.
Computational and theoretical approaches provide an essential vehicle for better understanding
of systems to help close the enormous gap between available data and their biological discovery.
The solutions include computational modeling of biological processes, data mining, algorithm
development and high-performance computing, as well as statistical and mathematical anal-
yses. During pathway analysis, there are three main approaches: those that are data-driven,
knowledge-driven and a combination of the two former approaches. A data integration tool’s
purpose is to incorporate various biological resources from the scientific literature to knowledge
databases with genome and protein sequences, motifs and structures to interpret them biologi-
cally.
Pathway analysis requires a global perspective on the data and solutions of problems at
hand for greater findings from real experiments. In fact, pathway analysis is intended for re-
search to gain insights into high-throughput biological data. As a main part of a pathway,
genes relate to one another through intricate networks of interactions, entities and annotations
1
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instead of individually. In-depth and context-dependent findings can assist in interpreting the
mechanisms of disease and how to intervene therapeutically during disease processes. Further,
pathway analysis must progressively satisfy a number of core requirements to gain data insights:
data-driven (experiments, data structure, statistics, and data integration) and knowledge-driven
(literature surveys and other knowledge-based sources, prior knowledge through gene ontology
and other ontologies). Among these requirements, data integration and prior knowledge are
generally more important than the rest of the requirements. For instance, despite significant
efforts by researchers and practitioners, to the best of our knowledge, there has been no de-
ployment of a fully functional annotated pathway system that supports all the search patterns.
Another example that is somewhat surprising is that it is difficult to simultaneously archive prior
knowledge and data integration in a comprehensive tool for pathway analysis to further explore
functionality in real experiments.
Building a data integration tool is challenging. Data integration in this study includes
gene expression, clinical data, pathways, and somatic mutations. Gene expression as in a cen-
tral dogma is a process that features sub-steps: DNA to RNA via transcription and RNA to
protein by translation. Clinical data can include demographic information, diagnosis, treatment
and overall survival. Challenges of data integration are highly connected to data sources and
ontologies, heterogeneity with functions and structures, data analysis methods and incomplete
or overlapping data sources as well as frequent changes. One approach is machine learning
or classification program learning where expression data is collected and followed by applying
clustering method for gene partition and gene reassignment along with validating independent
cohorts of patients. Other approach is data mining or other artificial intelligence techniques,
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where data-driven and knowledge-driven are combined, to analyze data from different perspec-
tives, associate them with clinical data and finally summarize them into useful patterns.
With a background in computer science, the author has been intrigued by designing bioin-
formatics algorithms (e.g., alignments, annotation, encoding data, imputing controls and han-
dling missing data). Further, various topics in terms of molecular biology pathways (e.g., in-
teractions, entities, annotations) have been studied. The first includes gene-gene and protein-
protein interactions (e.g., activation, inhibition, regulatory). There are multiple entities in a
pathway (ligands, receptors and other complexes within upstream routes and TFs, co-factors,
downstream targets of these factors and biological processes). Annotation requires alignments,
quality control and mapping with a reference library. Moreover, the author quickly realized
that there is a tremendous gap between designing bioinformatics algorithms and building a real-
world system for biologists. The latter requires knowledge and experience from different areas
and dedicated implementation. In addition, it necessitates creating practical systems that are
usable, efficient and reliable with demonstrable biological insights. As such, herein, described
is the design and implementation of numerous practical systems for deep pathway analysis with
provable accurate guarantees of biological insights. After collective efforts, a comprehensive
data integration “BioTarget” tool for pathway analysis was built. In the future, research will
continue to be conducted on computational biology and bioinformatics with different angles for
improved outcomes in the field.
4
1.1 Contributions
1.1.1 Large Scale Gene Set Comparison
Comparing one gene set against many gene sets is a method that is ubiquitously used in many
high-throughput gene expression studies. A conventional mean of comparing one gene set
against a large number of target gene sets is through database programming. However, this
approach can be inefficient if the sizes of the target gene sets become massively large. Therefore,
we proposed a coding scheme to convert both query and target gene sets into bit streams and
use bitwise Boolean operations, such as intersections and set differences, for comparisons. Our
approach can efficiently represent gene sets containing a small number of gene identifiers, thus
suggesting the feasibility of storing a large amount of target gene sets into memory entirely.
Our method drastically reduces disk I/Os, which are inevitable with a database programming
approach. Our method can offer a constant time performance independent of the size of the
target gene sets. This study will be discussed in Chapter 2.
1.1.2 Modification of Pathways
We proposed a method of constructing a gene/protein regulatory network specifically tailored
for assessing the disease state of a patient by combining generally known gene/protein pathways
with transcription level changes obtained by comparing the patient’s data with the average gene
expression data of the disease population. This approach employs histogram estimation with
conditional mutual information to identify if certain genes/proteins are more likely to interact
with one another. We applied our method to the Cancer Genome Atlas (TCGA) cancer data,
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specifically, RNA-seq gene expression data of 110 breast cancer, 141 colorectal cancer, 445
gastric cancer and 105 rectal cancer samples, which are publicly available. We focused on ex-
amining TFs such as SNAI1, SNAI2, ZEB2 and TWIST1 and their downstream targets within
the EMT pathway (e.g., OCLN, DSP, VIM, CDH2). We discovered that although the partici-
pating biological entities of the EMT pathway are generally known, our approach can extend
their regulatory relationships through novel members. With this, our approach could form the
basis for creating a novel means to construct a gene regulation pathway specifically tailored for
each individual cancer patient. The details will be presented in Chapter 3.
1.1.3 Surrogate Controls for Test Samples of RNA-seq data
In this work, a method for imputing controls for test samples is presented. This method we
refer to as subject-specific surrogate control, and it does not have matching normal samples.
We determined if this method using a subject-specific surrogate control produces any better
outcomes than the conventional method of utilizing the population average. We applied our
method to publicly available gastric and breast cancer data from TCGA to evaluate its effective-
ness. Our method functions as follows: First, we separated the test samples into two subgroups,
one having elevated levels of Epithelial-Mesenchymal Transition (EMT) pathway molecules
and another with the rest. Second, we performed Kaplan-Meier (KM) survival analysis for the
two identified subgroups. In both cancer cases, we observed that those patients with elevated
EMT had a poorer prognosis than the subgroup having non-elevated EMT levels. EMT-elevated
cancer patients having a poorer prognosis has been well-established in gastric cancer, but the
same observation for breast cancer case has not yet been reported. We hypothesize that some
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subtle differences cannot be revealed with a population control, though they can be discovered
if a subject-specific surrogate method is used, thus indicating potential merit for our newly
suggested subject-specific control imputation method. This will be discussed in Chapter 4.
1.1.4 BioTarget: A Data Integration Pipeline for Pathway Analysis
Molecular pathway curation includes mostly upstream signals that are well-known in the lit-
erature. However, the activities downstream of TFs are not well-studied. For example, the
downstream targets of TFs are hardly annotated in KEGG (a well-known pathway database).
The main goal of this pipeline is to explore a computational method that can help us find can-
didate target genes of a TF for a given molecular pathway and further, identify subgroups of
patients with a cancer prognosis that respond better to treat. Hence, we built an integration
tool, namely BioTarget, for TF target prediction utilizing the existing ChIP-seq binding sites
and the accompanying transcriptome data provided by RNA-seq. Our data mining technique
can correlate TF binding sites with activated or suppressed state target genes. The method we
propose allows us to identify TF targets that are unique to both spatial and temporal context
experiments. Enrichment pathway analysis of cancer signaling pathways (e.g., Th1/Th2 Cell
Differentiation, BCL6-mediated T-fh signaling) using BioTarget has several purposes: 1) To
understand how signal transduction is transcribed from upstream to downstream targets of TFs
(e.g., TBX21, GATA3, BCL6, TCF7/LEF1, JUN/FOS, MYC); 2) whether our proposed model
that utilizes the pathway structure with explored target genes and/or experimental pathways can
provide effective scores to show potential in determining poor prognoses for cancer patients;
and 3) whether our model can also yield an enriched target gene list and pathway structures
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for these signaling pathways. The pipeline and an analysis of the immune response will be
described in Chapter 5.
1.1.5 Pathway Analysis of Cell Proliferation Incorporating with Cell Differentiation
We applied our TF target prediction method to TCGA data sets to verify whether our method
can indeed extend the existing pathways with target genes. Specifically, we tested Cell Pro-
liferation pathways: Wnt, Mapk and IGF. Each pathway was added by over 30 target genes,
although this number could further be increased depending on the choice of cut-off thresholds
introduced in our data mining method. Subsequently, we demonstrated the significance of such
pathway extension by performing KM survival analysis. The results from our KM analysis
provided evidence that the extended pathways outperform the original pathways for survival
analysis. Five TCGA cancer cohorts we analyzed were gastric, lung adenocarcinoma, lung
squamous cell carcinoma, breast and colorectal. Among these cohorts, the extended pathways
perform better in four cohorts, excluding gastric for the Wnt pathway. TFs in these pathways
were TCF7/LEF1, MYC, JUN/FOS and STAT3. They are well-known for their roles in cell
proliferation and immunosuppression. In addition to these established aspects as TFs in cancer,
we used BioTarget to “newly” identify target genes of these TFs and explore functions coordi-
nating with cell differentiation in different micro-environments. We discovered that oncogenic
functions of TFs were dominantly activated in certain cancer cohorts. This result allowed us
to better assess of pathway signals of cell proliferation and cell differentiation in cancer. The
details of this study will be presented in Chapter 6.
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1.2 Organizations
This thesis is divided into 7 chapters. The motivation, background and contributions are pro-
vided in Chapter 1. Moreover, Chapter 1 features an introduction of the approaches in the
computational biology and bioinformatics field. Abstracts of works were also provided in this
chapter.
Chapter 2 presents a bitwise-encoding method for large-scale gene set comparison that
can offer a consistent time performance independent of the size of the target gene sets. This
method also reduced significant amounts of disk I/Os which are unavoidable with conventional
approaches.
Chapter 3 describes how to extend a biological pathway via a data-driven approach. Al-
though biological entities of the EMT pathway are generally known, through novel interpreta-
tion, their regulatory relationships have been extended. This approach also supplies a fresh way
of constructing a specifically tailored pathway for each cancer patient within a cancer cohort.
Chapter 4 introduces the method of inputting missing controls for test samples of RNA-
seq data. In this study, EMT-elevated cancer patients having a poorer prognosis has been well-
established in gastric cancer, but the same observation for breast cancer has not yet been re-
ported. Moreover, EMT-elevated populations have a poorer prognosis than the subgroup having
non-elevated EMT levels, though this is generally understood within the domain.
Chapters 5 and 6 detail a comprehensive solution for pathway analysis. BioTarget is a
data integration pipeline to address multiple pathways, including cell differentiation and cell
proliferation. Chapter 5 offers details of the pipeline and the results in terms of cancer immune
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response of cell differentiation. Meanwhile, Chapter 6 puts forth means of improving BioTarget,
the results of cell proliferation and the discussion of coordinating cell differentiation and cell
proliferation.
We conclude this thesis in Chapter 7 with suggestions for future work.
Chapter 2
A Bitwise Encoding Scheme for Large Scale Gene Set Comparison
2.1 Introduction
The current biomedical research community faces a significant challenge in handling the ge-
nomics data that is inundating the field. Particularly, the recent advance in Next Generation
Sequencing (NGS) technology has been dramatically changing the way biomedical scientists
analyze experimental data. One noticeable trend has been: (i) a group of closely collaborating
scientists produces massive amounts of data with a specific agenda in mind, (ii) they deposit the
collectively obtained data sets in a public repository, and (iii) the public uses them as references
for various types of research inspired by an individual laboratory’s interest. There are multi-
ple examples of such community generated genomics data projects. The 1000 Genomes project
aims at uncovering structural variations using whole genome sequencing on samples taken from
over 2500 individuals with known geographic and ethnic origins [1]. TCGA is to explore the
entire spectrum of genomic changes involved multiple human cancer types [2]. ENCODE aims
at identifying key functional elements in the human genome [3]. In addition there is a Gene
Expression Omnibus (GEO) which is a “catch-all” database repository of many different types
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of high throughput gene expression data which were submitted by thousands of scientists [4].
All these public data sets wait for utilization by bioinformaticians or computational biologists
at large.
We have been analyzing numerous high-throughput gene expression data in attempts to
help many local biomedical scientists derive meaningful interpretations from their respective
experiments. Steps include, for example, sub-grouping gene expression patterns using cluster
methods like a Pattern-Based clustering (PBC) program [5] and then performing the subsequent
“meta-analyses” [6]. Typically two types of meta-analysis can be attempted: (i) enrichment
analysis (e.g., WebGestalt [7]) and (ii) comparing the locally generated data with the similar
publicly available or related ones. Both approaches involve gene set comparisons. Enrichment
analysis includes comparing a “query gene set” (e.g., differentially expressing “DE” genes)
against the “target gene sets” such as well-curated collections of gene sets in Gene Ontology
or pathway databases (e.g., KEGG). The goal is to find whether or not query set includes an
unexpectedly large number of genes of some a prior known functional group(s). For example,
biologists can discover if the identified DE genes clearly point (towards) that “Wnt signaling
pathway” is suppressed or whether they are more or less involved in the biological process
known as “osteogenesis” and so on. Typically Fisher test is used to produce a p-value which
measures the statistical significance of the enrichment. Unlike the first approach, the second
approach comparing the DE gene set against the data set available from the public repository
is not well-established. In fact, how to carry out the second type of analysis is an active area
of bioinformatics research; there are many alternative ways of exploiting the genomics data
publicly available and how to use data to better analyze DE genes is a widely-regarded question.
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Nevertheless, we conjecture that most of the comparison studies will involve comparing DE
genes against some target gene sets of many different types (e.g., gene sets derived from ChIP-
Seq, ChIA-PET, microRNA, RNA-seq, DNA-Seq, etc.). As the scale and magnitude for such
gene set comparison is rapidly increasing, it is imperative to design an efficient way of carrying
out the gene set comparison.
2.2 Problem Formulation
Figure 1 contrasts the two methods for doing the gene set comparison, one using the conven-
tional database programming and one using the coding scheme we report in this chapter. First,
lets say there is a very large collection of gene sets, say, a database of target gene sets, which
is denoted by DBt = {G1,G2, . . .Gn}. Here each Gi,1 ≤ i ≤ n, includes one or more gene
identifiers. Let there be, namely, a query gene set, Gq, which also includes one or more gene
identifiers. The goal is how fast one can compare the query set Gq, with each gene set stored
in DBt , which should be typically stored in a database. Figure 1a illustrates the database pro-
gramming approach. One can write a SQL statement that performs intersection between Gq,
and each gene set in DBt . In this approach the DBMS will fetch a group of gene sets from
the database (via disk I/O) and carry out the intersection in memory. Figure 1b illustrates the
scenario in which someone designs an effective data compression method, the entire gene sets
of DBt can be stored in the memory and the entire intersection operations can occur in memory.
As the figure suggests, each target gene set of DBt is encoded once and the encoded gene set is
stored in the disk. This encoded gene set of DBt is read once and can reside in memory and is
repeatedly used in comparing a series of input query gene sets. Our coding scheme approach
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would be far more efficient than the SQL based approach because processing of each target
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Fig. 2.1: SQL-based approach and coding approach with memory and disk I/O usage in both
approaches.
One issue in our approach is estimating realistically how big a DBt our coding scheme
can store in memory of an ordinary computer workstation. Our plan is given a byte (8 bits),
we use one bit to present a gene identifier. Each byte ranges from 00000000 to 11111111 and
each bit position in the byte is tied to a gene identifier uniquely. Each byte can then repre-
sent up to 8 gene identifiers depending on which bit is set to “1” as opposed to “0”. If we
assume the size of the entire known human genes is 24000, this coding scheme will entail up
to 3000 bytes (= 24000/8) to express a gene set including the entire known human gene iden-
tifiers. If we estimate that a typical DE gene set has less than 1000 genes in it, then this coding
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scheme may need to use up to 1000 bytes. The worst case is when only one bit is set in each
byte. A different coding scheme can be used which can squeeze in up to 28− 1 = 255 gene
identifiers in a byte. In this case only about 100 bytes would be enough to store the entire 24000
genes. The former encoding scheme has a lesser data compression factor but the bitwise opera-
tion needed in this scheme is far more straightforward than the one needed in the latter coding
scheme. In the former scenario, DE sets from one million experiments can be stored in 1GB
memory which is affordable in typical workstation computers.
The rest of the chapter is organized as follows. In Section 3, we present related works of
using bitwise coding schemes in genomics data analysis. In Section 4, we provide the basics
of bitwise data structure and the associated Boolean operations. We also discuss other topics
related to motivating the use of the encoding scheme. In Section 5, we describe the details of
how gene sets are encoded and decoded, and how encoded gene set data structure is processed.
The running time complexity of the operation is also analyzed and discussed. Section 6 is the
conclusion.
2.3 Related Works
Two of the tools applying bitwise data structure and operations to perform high-throughput data
analysis are BiForce [8] and BOOST (BOolean Operation-based Screening and Testing) [9]. In
BiForce, the goal is to uncover gene-gene interactions (epistasis) from genome-wide association
studies (GWAS). It uses Boolean bitwise operations and multithreaded parallelization to speed
up comparisons of billions of single nucleotide polymorphism (SNP) combinations obtainable
from a pair-wise genome scan. Its coding scheme introduces three types of genotype in which
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x, 0≤ i≤ 2, is set to 0 or 1 among 3 bits depending on whether the genotype
is present or missing. By default, all bits are set 0. If a genotype is present, one and only one of
3 bits is turned on as 1, otherwise, none of 3 bits is set. For example, let S01 = |1 0 1| denoting
genotype 0, and S12 = |1 1 1| denoting genotype 1. Then by using the bitwise AND operation
on each pair in S’s and counting the 1’s of the outcome, one can produce the binary traits table,
say, n1,2 = |S01∧S12|= |1 0 1∧1 1 1|= |1 0 1|= 2. The authors report that BiForce completed
analyses of the eight metabolic traits within 1 day on a 32-node cluster computer, identifying
nine epistatic pairs of SNPs in five metabolic traits and 18 SNP pairs in two disease traits using
two sets of about 340K SNPs from GWAS cohorts.
BOOST also uses bitwise data structure and operators on epistasis data obtainable from
GWAS. The authors introduce a Boolean representation of genotype data. Each row is to rep-
resent one specific type of genotype consisting of two-bit strings: one obtained from control
samples and the other obtained from test samples. Each SNP has 3 rows for three types of
genotypes instead of one row as in BiForce. Each bit in the string represents one sample, and its
value (0 or 1) indicates whether the sample has the corresponding genotype or not. The authors
give an easy to follow example in [9] illustrating that the method uses the bitwise operation
AND on each corresponding row, then counts the number of 1’s (e.g., hamming weight) taking
the advantage of 64 bit AND operation.
There have been other works in bioinformatics that also exploit bitwise operation. A
coding scheme and bitwise operators have been applied to mapping high-throughput bisulfite
sequencing reads to the reference genome in the system called BSMAP [10]. BSMAP combines
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genome hashing and bitwise masking to achieve bisulfite mapping where DNA sequences are
converted into binary strings by encoding each DNA nucleotide into two bits (i.e., A: 00, C: 01,
G:10, T:11). The authors suggest that due to this encoding scheme high-throughput bisulfite
reads can be mapped at whole genome level with feasible memory and CPU usage. We note
that none of the aforementioned existing works uses the coding scheme of our work presented
in this chapter.
High throughput computing requires that the tool should aim to “gene sets” instead of
individual gene. Gene set interactions with multiple categories have been integrated into an
analysis toolkit called WebGestalt from Wang et al. [7]. Recursively applying on a pair inter-
action makes it possible to combine information from any number of gene sets. However, it
has a limitation of performing multiple combinations at the same time in some experiments.
Oftentimes, the comparisons of all combinations will show a bird’s eye perspective and better
understanding the biological system. We also want to calculate the information content vari-
ables (e.g., information gain) for enrichment analysis of gene set interactions. Other interactions
such as gene and gene or gene and environment ones have been discussed [11], and in general
perspective of genetics [12].
2.4 Methods
2.4.1 Bitwise Conversion
Boolean logical operation has been used widely for the query system which computes typical
comparisons such as intersection and set difference. In order to compare two gene sets using
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bitwise operator, we need to convert the gene set into bits. For example, let A and B be two DE
gene sets obtained from two experiments. Performing intersection of the two gene sets could be
finding the genes that are consistently up- or down-regulated in both experiments. Difference
query displays the genes that are expressed in experiment A but not in experiment B, or vice
versa [7]. Figure 2.2 is an example of bitwise encoding and bitwise AND operation between
query and target gene sets.
Fig. 2.2: A hypothetical example of performing logical bitwise AND operator between query
gene set and target gene set.
Bitwise encoding is a conversion process of the query and target gene sets into coded key
and value map. We will segment the total genes into an eight bit format. For example, let 20000
be the total number of universe genes. Then we will have 20000/8 = 2500 keys (bytes) with
each key representing presence of 8 genes in a gene set. The genes in key k (1 ≤ k ≤ 2500)
represents genes which have index from (k−1)∗8+1 to k∗8. If gene i exists, the gene position
index will be calculated using modular 8 calculation, because we have an 8 bit structure. In
Figure 2.2, in query gene set, key 1 has one gene (gene 1), key 2 has 1 gene (gene 9), and key 3
has 4 genes (17, 21, 22, 23), and key 2500 has one gene (19993). Similarly target gene set has
genes with ids of 5, 9, 17, 22, 23, 19996. We apply AND bitwise operator between value of a
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specific key of query gene set and the same key in the target gene set. Genes with ids of 9, 17,
22, 23 are in common and there is no common gene in key 2500.
2.4.2 Bitwise Coding Approach for Gene Set Comparison
In this section, we describe new bitwise coding approach and compare it with the SQL-based
approach. The work flow of bitwise approach is shown in Figure 2.3.
It consists of three major steps: encoding, operating and decoding. In encoding phase, the
universe gene set, target gene set and query gene set are collected and encoded into a bitwise
structure with key and value pair as described in Section 4. Encoding universe gene set and tar-
get gene set is performed off-line. Gene encoding table contains keys and values for every gene.
If a gene is present in the set, the corresponding key and value are generated. Encoded gene
sets are archived in the database, and loaded into the computer memory when the computation
is needed.
Operating phase is performing a comparison between the input query set against the en-
coded target gene sets to produce various parameters (e.g., information gain, ratio, count. etc.)
which will be needed to derive biological interpretations. One noticeable fact is that such com-
parison can be performed entirely in memory (see Figure 2.3). Decoding phase is to translate
the comparison output obtained in bit-wise structure into a list of gene identifiers. This transla-
tion step will need to use a decoding table that specifies how the key and value of each gene are
mapped into gene identifiers. Such decoding will be an one-time process and can be done off-
line only when doing so is needed. The decoding process is (key−1)∗8+value. For example,
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Fig. 2.3: The work flow of coding approach has three steps: encoding, operating and decoding.
Encoding phase has two off-line steps for encoding universe gene set and all the target
gene sets once into memory. Decoding phase includes one off-line step to create
decoding map.
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the universe gene set. Three steps denoted in Figure 3 as “Offline” are processes of encoding
the universe gene set, encoding the target gene set and generating the decoding map.
Figure 2.4 shows the work flow of the alternative SQL-based approach with two major
steps: loading phase and operating phase. Loading phase includes reading target and query gene
sets. Here, the DBMS query system will be responsible for generating the output of comparing
the input query gene set and the database stored target gene sets. This SQL-based approach will
incur disk I/Os to bring in blocks of target gene sets into the memory which would become the
dominating factor responsible for making the SQL-based comparison process slow.
2.4.3 Computing Information Gain
To illustrate how bitwise operations can be used on coded data structure, we show an example of
computing information gain by comparing a pair of gene sets. Figure 2.5 depicts the overview
of the process, which is analogous to construct a decision tree [13]. In Figure 2.5, each node of
the tree contains a question. Every internal node points to one child node as a possible answer
to its question and the questions are formed into a hierarchy. In decision trees, one of the most
commonly used measurements is entropy. To estimate how a pair of gene sets are inter-related,
let H(X) and H(Y ) be gene set entropies for X and Y , respectively. Overlapped region in Figure
2.6 is I(X ;Y ), the mutual information derived from both patterns (e.g., joint distribution) and
H(X |Y ) and H(Y |X) denote conditional distributions (see Figure 2.6).
X is a set of possible values x1,x2, . . .xn and corresponding probability distribution p(xi) =
P(X = xi), i = 1,2, . . .n. The entropy of X is H(X), calculated as in Equation 1.
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Fig. 2.4: The work flow of SQL-based approach has two steps: loading and operating. It needs
lots of disk I/O usage for real-time computing.
Fig. 2.5: Example of three gene set pairs A-B, A-C and A-D. Decision tree goes from one node
to other nodes that depends on the constraints of the nodes. It chose gene set as the


















Mutual information is defined as the mutual information in both random gene sets X and
Y in Equation 2.
I(X ;Y ) = H(X)+H(Y )−H(X ,Y ) (2.2)
Target gene set and query gene set are assumed to be statistically independent. The con-
ditional entropy X given Y can be measured. Likewise, the conditional entropy Y given X can
be computed using Equation 2.3.
H(X |Y ) = H(X)− I(X ;Y ) = H(X ,Y )−H(X)
H(Y |X) = H(Y )− I(X ;Y ) = H(X ,Y )−H(Y )
(2.3)
Figure 2.5 is given to illustrate the use of information gain in solving the following prob-
lem: Given a query gene set A and the three target gene sets (B, C, D), can one determine which
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target gene set is more predictable of the given query gene set? To solve this problem we need
to build the contingency table as illustrated in Figure 2.6 for each pair of gene sets (e.g., A-B,
A-C and A-D). The table has four components which are labeled, respectively, true positive
(TP), true negative (TN), false positive (FP) and false negative (FN). Given the pair of target
and query gene sets, TP value is number of common genes between the two gene sets. TN/FP
are number of genes present in query/target gene set but absent in target/query gene set. FN
value is the number of universe genes that are neither in the target gene set nor in the query
gene set. We discuss in the subsequent section how fast information gains can be computed
using our proposed encoding scheme.
2.5 Case Study and Discussion
In our case study, we have implemented bitwise coding method and compared the results with
SQL approach using a randomly generated dataset of 30 query gene sets (Q1,Q2, . . . ,Q30) and
1000 target gene sets (T1,T2, . . . ,T1000). The number of genes in each set varies from 51 to
499 and is randomly selected from universal pool of 20000 genes. The target gene sets are
encoded and stored in variable number of blocks ranging from 73 to 143. We have analyzed
this dataset by running both SQL and bitwise approach to identify top five pairs Pi (Q j,Tk)
for two comparison cases: Intersection and Mutual Information Content. Our goal is to identify
intersection between query genes sets (Qs) and target genes sets (Ts) and also to identify mutual
information contents (difference) in each pair. To balance the environmental factors, we run
each experiment 10 times and report average running time. We also discuss time complexity of
the methods and briefly explain the performance benefit.
24
2.5.1 Gene Set Intersection
Algorithm 1 identifies top five pairs of Qs and Ts for highest intersection of genes. In this
algorithm, gene sets are compared using conventional SQL-based approach where two tables
are joined and row counts are generated using a Oracle DBMS. We compare all the possible
pairs and rank the pairs based on the number of common genes.
Algorithm 1 Generate Top5 Intersection use SQL
1: Initialize variables and database connection.
2: Read target gene set.
3: Read query gene set.
4: for (all queries) do.
5: Read target gene set and match gene id and output the ordered list of gene set id and
count.
6: Get the first element of list
7: Look up the Map with this element and store query list.
8: end for
9: Sort the query list.
10: Output top five of gene set combinations.
In algorithm 4, we have used bitwise approach to achieve the same goal as Algorithm 1.
The target gene sets are assumed to be already encoded and stored in the database. The encoded
sets are loaded into the memory in key-value HashMap for each block. This facilitates efficient
comparison between two sets using the block. A fast bitwise AND operation is performed for
every common block of both sets. A result map is created and result of bitwise operation is
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stored as values for those corresponding keys.
Algorithm 2 Generate Top5 Intersection use Bitwise
1: Initialize variables and environment, database connection.
2: Read target gene set.
3: Read query gene set.
4: Encode list of target gene set maps
5: for (all queries) do.
6: Encode query map of index and value.
7: Retrieve target map given target id.
8: Get AND value of pair-wise of query map and target map into a list.
9: Sort the list descending.
10: Get the first element of list
11: Look up the map with this element and store query list.
12: end for
13: Sort the query list.
14: Output top five of gene set combinations.
Encoding and loading of target sets are considered offline because they can be pre-loaded
into the program. Query sets need to be encoded once, and can be compared with all the loaded
target sets. Loading of decoding table can also considered offline because it is pre-loaded into
the program. Quick decoding is performed for all the keys in the result map and number of
intersecting gene is computed by adding decoded values for all the existing keys in the result
map.
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2.5.2 Mutual Information Content
Mutual information content is computed in terms of information gain (IG) using both the meth-
ods. Algorithm 3 illustrates SQL-based approach to compute information gain between each
possible pairs of query sets and target sets. We first create conditional table using set of SQL
queries and use this table to compute information gain. Each pair of sets and their information
gain are stored in a list and top five pairs are extracted by sorting the list in descending order
of their corresponding IGs. Information gain is also computed using bitwise approach for the
same dataset.
As illustrated in algorithm 3, conditional table is generated using bitwise AND operation
and the values are used in computation sequence of the algorithm for final result.
Figure 2.7 shows average running time for one pair of query set and target set for two
approaches. It is clear that TP in conditional table is computed significantly faster in bitwise
approach than SQL approach. Even with decoding overhead, it is observed that True Positive
(TP) calculation in bitwise approach takes seven times less than that of SQL approach. IG time
only includes the calculation time when having all elements in conditional table.
SQL approach is directly dependent on the number of genes in each set and also number
of sets that are being compared against. As shown in Figure 2.8, running time for SQL approach
is increasing linearly with the number of target gene sets. On the other hand, performance of
bitwise approach is very consistent and is not affected much by the number of target sets. For a
small number of comparisons, bitwise method performance is comparable with SQL approach,
however, it performs significantly better as the number of comparison increases.
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Algorithm 3 Generate Top5 Difference use SQL
1: Initialize variables and database connection.
2: Read target gene set (target id and count).
3: Read query gene set (query id and count).
4: Encode list of target gene set maps
5: for (all queries) do
6: Read target gene set and match gene id and output the ordered list of gene set id and
count.
7: Calculate the conditional table values and information gain, store into a list
8: Sort the list descending.
9: Get the first element of list
10: Look up the Map with this element and store query list.
11: end for
12: Sort the query list.
13: Output top five of gene set combinations.
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Algorithm 4 Generate Top5 Difference use Bitwise
1: Initialize variables and database connection.
2: Read target gene set (target id and count).
3: Read query gene set (query id and count).
4: Encode list of target gene set maps
5: for (all queries) do
6: Encode query map of index and value.
7: Retrieve target map given target id.
8: Get AND value of pair-wise of query map and target map into a list.
9: Calculate the conditional table values and information gain, store into a list.
10: Sort the list descending.
11: Get the first element of list.
12: Look up the map with this element and store query list.
13: end for
14: Sort the query list.
























































Fig. 2.7: Comparison of average running time for calculation of four elements in conditional
table and information gain for a combination of target gene set and query gene set.
We also experimented with the efficiency of coding approach by checking the time taken
by the program for sets with various number of genes. Conventionally with SQL, bigger sets
will make the process slower. However, the proposed bitwise approach is not much affected by
the number of genes in the set because the encoded data structure size is more or less fixed.
0
Fig. 2.8: Running time of 1 query, 2 query and 3 query gene sets in comparisons with 100 target
gene sets.
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1 query − Bitwise
10 queries − Bitwise
20 queries − Bitwise
30 queries − Bitwise
1 query − SQL
10 queries − SQL
20 queries − SQL
30 queries − SQL
Fig. 2.9: Running time of 4 types of bitwise queries (1 query, 10 queries, 20 queries and 30
queries) and 1 query using SQL in comparisons with 1000 target gene sets.






















1 query − Bitwise
10 queries − Bitwise
20 queries − Bitwise
30 queries  Bitwise
1 query − SQL
Fig. 2.10: Running time of 30 query gene sets in comparisons with 1000 target gene sets. Each
comparison includes a query gene set and a target gene set.
Figure 2.9 and Figure 2.10 show the speed comparison for entire information gain compu-
tation. When calculating information gain with SQL, average running time increases linearly to
the number of target gene sets. However with the proposed bitwise method, it is virtually con-
stant with the number of target gene sets. Figure 2.9 is the average running time of the program
of 30 query gene sets in combinations with 1000 target gene sets. Figure 2.10 shows the aver-
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age running time of 1 query, 10 queries, 20 queries and 30 queries using bitwise approach and 1
query using SQL approach. We can see that the operation time of bitwise computation increases
constantly even when the size of input sets and comparison sets increase in our experiments.
2.5.3 Time Complexity
In this section, we analyze time complexity of both approaches. The running time analysis for a
single interaction between a query gene set and a target gene set for our bitwise coding approach
can be explained as follows. Let nq be the number of genes in query set, Bq be the number of
blocks in this set and Bt be the number of blocks in the target gene set. The total time can be
calculated by aggregating running times to encode query set, compare query gene set and target
gene set, and decode the result (see Equation 4).
Cbitwise =Cenc +Ccomp +Cdecode (2.4)
Cenc is the time to read all genes in a query set and encode into key and value format.
The complexity is equal to the input size when reading all the indexes into an array. Therefore,
Cenc =O(nq) since nq is the number of genes in a query set. Ccomp, is the time taken to compare
the blocks with indexes that are common in both sets. In order to do this, we only need to
scan min(Bq,Bt) number of blocks. We have Ccomp = O(min(Bq,Bt)). When Bt = Bq, the
computation time is linear with the function of Bt (or Bq). And finally, decoding time Cdecode is
the time to look up decoding table which has the same data structure of blocks, i.e. Cdecode =
O(min(Bq,Bt)). Thus, average running time (same order as Equation 4) is presented below.
Cbitwise = O(nq)+O(min(Bq,Bt))+O(min(Bq,Bt)) (2.5)
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For SQL approach, time complexity is the time to look up the database to retrieve the
result (see Equation 6). Let nt be the maximum number of genes in a target gene set.
CSQL = O(nq)+O(max(nq log(nq),nt log(nt))) (2.6)
In this approach, both sets have to be sorted and that takes time O(max(nq log(nq),nt log(nt))
since the average sorting time of n indexes in an array is O(n logn). When nt = nq, the running
time will be O(nq)+O(nq lognq)≈O(nq lognq). Now if we compare the time complexities of
bitwise approach and SQL approach, we have CbitwiseCSQL. Bitwise coding method which
encodes the universe gene set and target gene sets offers a way to compare two gene sets with
the minimum number of blocks (bytes). In this approach the missing blocks (e.g., block with
all zero values.) can be totally ignored in the comparison, thus offering a greater memory space
saving and reduction in bitwise operation.
2.6 Conclusion
Gene set comparison is one of the key essential operations that is universally needed in many
high-throughput genomic data analyses. Examples include functional enrichment analyses,
ChIP-Seq peak finding, gene-gene interaction analysis, and so on. One important observation in
these gene set comparison practices is that the majority of the processes is finding and compar-
ing memberships of gene identifiers (in hundreds) in a large number of gene sets (in millions).
We presented a gene identifier encoding scheme which could store a very large number of gene
sets entirely in memory. This coding scheme suggests the feasibility of storing the target gene
sets in memory and using it over and over again for the analysis of the high quantity of arriving
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query sets. Such an arrangement can be very useful in supporting learning methods and data
mining methods which need to test a large number of gene identifier combinations against a
fixed albeit large number of target gene sets. Our case studies demonstrated our coding scheme
could offer linear time performance proportional to the number of arriving input query sets.
Chapter 3
Modification of Pathways by utilizing Conditional Mutual Information Extracted
from RNA-seq data
3.1 Introduction
RNA-sequencing (RNA-seq) data has been gradually gaining popularity over microarray data
for better understanding disease etiology. RNA-seq is generally used for genome-wide analysis
of transcriptome signals and it can be very effective in identifying enriched molecular func-
tions which are overly activated or suppressed [14], [15]. Our study focuses on analyzing a
particular set of transcriptional activities, namely Epithelial-Mesenchymal Transition (EMT).
EMT is a process by which epithelial cells lose their cell polarity and cell-cell adhesion, and
gain migratory and invasive properties to become mesenchymal stem cells. EMT is a reversible
and dynamic process hypothesized to be co-opted by carcinoma during invasion and metasta-
sis. Some studies focused on quantitative measures to assess the interaction between EMT and
cancer progression [16], [17].
In this chapter, we present a method for customizing EMT pathway from cancer-specific
transcriptome signals. The key idea of our approach is that the community curated gene and
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protein pathway can be “tailored” to be more specific to sub-typed cancer patients. Community
curated pathways are for the general population and our goal is to examine if these generic
pathways can be modified to a different version which could reflect a patients situation more
accurately. Figure 1 illustrates this pathway revision process. The original pathway is used to
produce two alternatives, one to add new relationships and one to remove existing relationships.
These two alternatives are then merged to create the customized version with the anticipation
that the final merged version better describes the pathway relationships of a particular group of
patients. This chapter addresses three issues: (i) presenting theoretic bases for making pathway
modification, (ii) demonstrating experimental outcomes obtained by applying our method to
publicly available cancer data, and (iii) reporting this pathway modification can indeed improve
the analysis of transcriptome data.
3.2 Related Works
Inferring gene regulatory networks has been extensively studied. Zhang et al. (2012) proposed
a method of inferring gene regulatory networks utilizing microarray gene expression data com-
bining with path consistency algorithm based on Conditional Mutual Information (CMI) [18].
Zhou et al. (2014) also applied CMI into pathway to identify the hub genes which acts as the
common link to and from the hub nodes in a graph [19]. However, to the best of our knowledge,
neither of these existing works aims to modify human curated pathway. Instead, their work is
to denovo generate gene regulatory networks, often resulting in a hairball structure which is
mostly incomprehensible.
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Fig. 3.1: Illustration of customization process to extend, prune and merge nodes and edges in
biological pathway.
3.3 Materials and Methods
3.3.1 Data Set Pre-Processing
RNA-seq data of four cancer types, breast, rectal, colorectal and gastric, were obtained from
the TCGA public website. Table 1 shows the details of the downloaded data. We note that this
downloading was limited to RNASeq2 of two types, solid tumor (code 01) for test samples and
normal/ blood tissue (code 11) for control samples.
RNA-seq values with expression equal to zero across all samples were filtered out. The
log2 of fold change between tumor samples and control samples is calculated. Any alias or
37
Table 3.1: The number of case and control samples for each cancer type.
Dataset #tumor samples #control samples
Breast cancer 100 10
Colorectal cancer 100 41
Gastric cancer 410 35
Rectal cancer 95 10
synonyms are converted to official gene symbol using our locally developed gene-annotation
web service.
3.3.2 Information Theory
Mutual Information (MI) from information theory has been used to construct gene regulatory
network from gene expression data [5, 6]. Our approach is using the technique of conditional
likelihood maximization as doing so has been suggested in [7]. MI has been used to compare
information content of large-scale gene sets [8]. In particular, MI can be a good measurement
of the dependence between two variables, say, gene X and gene Y. When using RNA-seq data,
variable X can be a vector of numeric values where each value denotes the mRNA expression
fold difference in a pair of related samples.
Given two genes, X and Y, then the mutual information (MI) can be used as a measurement
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representing the dependency between X and Y such as:





High MI value implies that there may be a close relationship between genes, while low
MI value indicating their independence. CMI measures conditional dependency between two
genes given expression pattern of other gene(s). The CMI of variable X and variable Y given Z
is defined as:
I(X ,Y | Z) = ∑
x∈X ,y∈Y,z∈Z
p(x,y,z)∗ log p(x,y | z)
(p(x | z)∗ p(y | z)
(3.2)
Similar to MI, high CMI indicates that there may be a close relationship between X and Y
given Z. Our plan is to use this CMI as a formal way of encoding relationships expressed in a
gene/protein regulatory pathway.
3.3.3 Pathway modification analysis
(a) Inferring interrelationships between target genes: We show a hypothetical example il-
lustrating how CMI/MI can be used for inferring new relationships. Let T F1 be one of the
transcription factors (e.g., SNAI1, TWIST) and let downstream targets, say, Gene 1 and Gene
2 be up-regulated genes (e.g., CDH1) and Gene 3 and Gene 4 be down regulated genes (e.g.,
FN1). Gene A be a gene which has high MI with Gene 1 and Gene 2 possibly be regulated by
T F1. Likewise, if Gene B interacts with Gene 3 and Gene 4, it is likely to be down-regulated by
T F1 (See Figure 3.2).
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Fig. 3.2: Left: Up-regulated genes mostly interacted with Gene A and Right: Down-regulated
genes mainly connected with Gene B. Both Gene A and Gene B are likely to have
connection with T F1.
(b) ME score for pathway consistency: Three types of elements are involved in a path-
way: (i) a biological process of interest (e.g., EMT), (ii) one or more genes (typically transcrip-
tion factors) which are known as marker genes (e.g., SNAI1, TWIST and ZEB) for the con-
cerned biological process, and (iii) direct or indirect downstream targets of the marker genes of
two types, called Suppression genes (e.g., CDH1) and Activation genes (e.g., FN1). A scoring
measure ME score which ranges between 0 and 1 where 1 signifies the maximal enrichment
of the biological process. ME is computed as a ratio of consistency frequency over the size of
target genes where the consistency frequency is a count of marker genes whose behaviors are
consistent with what have been specified in the pathway (i.e., up-regulated for Activation or
down-regulated for Suppression). We are using ME score to determine the impact of pathway
customization to pathway diagram of each individual person for each cancer type (e.g., gas-
tric cancer). Table 3.2 is summary of applying this customized pathway to five breast cancer
patients whose the ME scores changed.
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Fig. 3.3: Customized pathway for breast cancer with transcription factor ZEB2. DSP is added
into down-regulated target genes of ZEB2.
3.4 Result and Discussion
(a) Experimenting with breast cancer data: We set high MI as greater or equal 0.2 and low
MI as less than 0.001. In this case DSP is added as a suppressed gene by the EMT inducer
ZEB2, just like CDH1.
The data shows that breast cancer patients may have very little difference in their ME
scores before and after modification of EMT pathway. Later in (e) this change is compared with
improvements observed in other cases. (b) Experimenting with colorectal cancer data: Here 0.6
has been used as upper bound threshold of MI value for extension and 0.002 has been used as
the lower bound threshold for pruning. Compared to other types of cancer data, the amount of
variation of MI values is far bigger in this cancer type. One interesting observation we made
here is that majority of gene-pair mutual information is relatively small. One clear outcome of
this analysis is that JUP is now added as one of SNAI2s suppressed gene group such as OCLN
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Table 3.2: The ME score before and after customizing for breast cancer.






and CDH1. Figure 3.2 illustrates such change.
(c) Experimenting with rectal cancer data Here we used [0.5, 1] and [0, 0.02] as bound-
aries for adding or deleting nodes/ edges. As a result, SPARC is added into the suppressed
target gene group of the transcription factor ZEB2 (See Figure 3.5). The changes in ME scores
of rectal cancer patients are observed to be much greater than those with breast cancer.
(d) Experimenting with gastric cancer data The scores changed significantly with gas-
tric cancer where MI values for extending and pruning thresholds are 0.4 and 0.01. The outcome
was strikingly similar to the rectal cancer case where SPARC is added into SNAI2 suppressed
target group. Figure 6 illustrates the change. The details of ME scores of gastric cancer patients
before and after using customized pathway can be found in Table 3.3.
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Fig. 3.4: Customized pathway for colorectal cancer with transcription factor SNAI2. JUP is
added into up-regulated genes target group of SNAI2.
Fig. 3.5: Customized pathway for rectal cancer with transcription factor ZEB2. SPARC sup-
pressed by ZEB2 is added into down genes group.
(e) Evaluation with ME score In order to examine if the newly extended pathway is
better or worse, we ran ME score analysis and compared how the ME score changes before and
after the pathway modification by a test statistics (e.g., t-test). Earlier in Table 3.2 and Table
3.3 we showed the summary of the score improvement after the modifications, respectively, for
breast and gastric cancers. Figure 3.7 is the summary of the ME score changes in tumor samples
before and after the pathway customization in all four case cases. Rectal cancer has the most
dramatic ME scores change. In gastric and colorectal cancers, ME scores change is slightly
lower than in case of rectal cancer. However, the changes are still significant. In contrast, in
breast cancer case, the improvement is rather modest, compared to other cases. EMT pathway
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Table 3.3: The ME scores before and after customizing for gastric cancer.






needs more revision on rectal cancer than other cancer cases.
3.5 Conclusion
We presented a method of extending a protein/gene regulatory pathway into a better one by
eliminating gene regulatory relationships or adding new relationships where these extensions
are inferred by analyzing RNA-seq data. We used Conditional Mutual Information with his-
togram estimation for the pruning and extension. As a case study, we applied our method to
a gene/protein regulatory pathway well known for cancer, called EMT pathway. We evaluated
our method with four types of cancer data sets, gastric, colorectal, rectal and breast cancers
that are available from the TCGA public web portal. One positive outcome of our evaluation
is that in three out of the four cancer data sets their corresponding modified/extended pathway
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Fig. 3.6: Customized pathway for gastric cancer with transcription factor SNAI2. SPARC sup-
pressed by SNAI2 is added into down genes group. As higher ME score is known for
worse cancer prognosis, ME scores change in more people may suggest more people
are EMT affected in gastric, rectal and colorectal cancer.
Fig. 3.7: The changes in ME scores for EMT pathway. No Change means ME score remain the
same and Change represents that ME scores are different across the number of patients
in four cancer types.
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produced increased consistency between the regulatory relationships of the EMT pathway and
the transcriptome data obtained from RNA-seq. For gastric cancer, our finding is consistent
with what is already known in the literature, that is, severe EMT cases are often found in gas-
tric cancers. Our negative finding on breast cancer EMT score may not be a good measure for
cancer prognosis is also consistent with finding of previous studies [16], [17]. Currently we are
working toward applying our method to larger and more diversified types of cancer data that are
available both in TCGA and other cancer research communities. Success of our future efforts
could suggest a new way of producing gene-protein regulatory pathways that are specifically
tailored for personalized cancer treatment.
Chapter 4
Surrogate Controls for Test Samples of RNA-seq data for Pathway Analysis
4.1 Introduction
In this work, we present a method of imputing controls for test samples that do not have match-
ing normal samples. We call the imputed one a subject-specific surrogate control. We study
if this method of using a subject-specific surrogate control produces any better outcome than
the conventional method of using the population average as the sole common control for all
test samples. For evaluation, we apply our method to publicly available gastric and breast can-
cer data from the Cancer Genome Atlas (TCGA). First, we separated the test samples into two
subgroups, one having elevated level of EpithelialMesenchymal Transition (EMT) and the rest.
Second, we perform the KaplanMeier (KM) survival analysis for the two identified subgroups.
In both cancer cases, we discover that EMT elevated population has a poorer prognosis than the
subgroup having non-elevated EMT level. EMT elevated cancer patients having a poorer prog-
nosis has been well established in gastric cancer, but the same observation for the breast cancer
case has not. We hypothesize that some subtle differences that cannot be revealed using the pop-
ulation control can be discovered if subject-specific surrogate method is used, thus suggesting
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a potential merit for our newly suggested subject-specific control imputation method.
High-throughput genomic sequence experiments (e.g., RNA-seq, DNA-seq, ChIP-seq,
etc.) produce generally two types of data, one for test sample and the other for control sample.
The subsequent analysis is to compute the ratio between two corresponding data points obtained
from the test and control samples ( [20], [21], [14], [15]). Studies typically include only a small
number of control samples while including a larger number of test samples to give the analysis
a greater statistical significance. In some cases, studies produce only test data due to specimen
or other limitations. One recurring issue is to determine which control value should be used to
compute the ratio between the test and control samples.
Two approaches are frequently used. One is to use the population average of all control
samples. The other is to use subject-specific control (i.e., the paired matching normal). When
only a small number of control samples are used, the typical approach is to use the mean values
of the control samples as a common control across all test samples. When control samples are
not available, the mean values of the test cohort are used as the common control. The method of
selecting the controls is fundamentally important in the field of genomic data analysis because
of its crucial role in the success of any subsequent meta-data analysis (e.g., gene enrichment
analysis of biological pathways or biological processes [22], [16], [17]).
In this chapter, we introduce a way of performing subject-specific analysis even if only
a small number of control samples is available. The underpinning premise behind our ap-
proach that the population-averaged control may ignore potential subject-specific effects, al-
though some argues that the population-average control provides a more stable analysis out-
come and would be less sensitive to individual’s bias ( [23], [24]). We counter such argument
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by performing a benchmark study using the publicly available TCGA data. The TCGA por-
tal includes a rich collection of both tumor (test) and normal (control) samples, thus providing
real-world genomics data for scientists to study and compare effectiveness of newly developed
methods. In terms of the specifics of benchmarking with the TCGA data, we choose the path-
way analysis as a tool for the evaluation. More specifically, we use Epithelial-Mesenchymal
Transition (EMT) signature which has been widely accepted in the cancer research community
as a measure to predict poorer prognosis for cancer patients. Higher EMT score means a more
aggressive form of cancer ( [16], [17]).
Figure 4.1 summarizes the work flow of our EMT signature analysis which includes three
steps: (i) impute control for each test sample which has no matching control (the outcome is
called a subject-specific surrogate control), (ii) carry out the pathway analysis method which
uses the imputed controls to produce a score representing how much the concerned pathway is
utilized in the biological system under investigation, and (iii) perform the KM survival analysis



























Fig. 4.1: Illustration of finding surrogate controls to be used in pathway enrichment analysis.
The rest of the chapter is organized as follows. In Section 2, we discuss previous works
introducing surrogate control in various case-control studies. In Section 3, we provide the
details of basic notions and methods introduced in our computation model. In Section 4, the
details of evaluation study are described. Section 5 is the conclusion.
4.2 Related Work
The idea of using surrogate control has been studied in the literature. Hu et al. (2005) extended
traditional effect size models to combine information from different microarray datasets by
incorporating a quality measure for each gene into the effect size estimation [25]. Their results
indicate that the proposed quality-adjusted weighting strategy for modeling inter-study variation
of gene expression profiles not only increases consistency and decreases heterogeneous results
between test and control datasets, but also identifies more differentially expressed (DE) genes
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than the conventional methods. Stuart et al. (2008) chose a subsample from the original control
group that matches the treatment group on the distribution of the observed covariates [26]. One
limitation of this group’s work is that they do not include any evaluation study demonstrating
the power of their modified control selection method.
Another approach is to use multiple control groups in case-control studies where different
sources of confounding factors are utilized. Cessie et al. (2008) introduced the idea where
cases can be contrasted with matched controls to adjust for multiple genomics differences even
if population-based control is used [27]. Here, the authors introduce a straightforward way
of estimating odds ratios from several case-control analyses. The estimated odds ratios have
been used in bootstrapping with confident intervals. This group also used a simulation for
performance evaluation in which a matched control group and an unmatched population-based
control group are compared. Finally, we note that these related studies mainly focus on simply
identifying statistically significant DE genes in genomics or clinical studies. None of these
existing works examine how their modified methods for computing control can be applied to a
complex data analysis like the one we discuss in this work.
4.3 Methodology
4.3.1 Relationship function
Let a high throughput sequencing experiment (RNA-seq, DNA-Seq, ChIP-Seq, microarray, etc.)
produce two sets of data, one for the control set {c1 . . .cm} and one for the test set {t1 . . . tn},
where m< n. Let m test samples have matching controls and let the remaining n−m samples do
51
not. If the experiment is an RNA-seq from human tissue, each sample may have an array of data
points < g1, . . . ,g25000 > where 25,000 is the estimated number of known human genes. Let the
test samples include m matching control samples as illustrated by Figure 4.2. The number of
control samples m can be smaller than number of test samples n. For example, only m normal
tissue samples were collected for the first m cancerous tissue samples and no normal sample
was collected for the rest test sample t(m+1) . . . tn. We denote m test samples and m matching
control samples as t1, . . . tm and c1 . . .cm, respectively.
t1  t2 ...  tm tm+1      ...      ti      ...     tn




Fig. 4.2: Each test sample may have different distance between f (ti,ci) and f (ti,c j) with vari-
ous control samples.
To apply our control imputation to the TCGA data, we first convert the downloaded RNA-
seq2 data into log2 ratio. Let vt and vc be two mRNA intensity values for a gene where vt is
from the test sample and vc is from the control sample. The following data pre-processing is
performed. For control sample, vc is defined as 1 if the mRNA abundance value of the gene
of a subject (i.e., valueg(c)) is greater than the population mean µg(c), i.e., landing in the
range [µg(c),∞). It is marked as 0 if the value is less than or equal to the population mean
µg(c), i.e., landing in the range (−∞,µg(c)). Similar data reconfiguration is applied to the test
sample. Then a contingency table (as illustrated in Table 4.1) for the control sample and the
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Table 4.1: The contingency table of control and test values of genes of a patient.
Control / Test vt = 0 vt = 1
vc = 0 a b
vc = 1 c d
test sample is built as follows: (i) a is the number of genes of a patient which have control
values smaller than the control population average and test gene expression values are smaller
than the test population average (i.e., vc = 0 & vt = 0), (ii) b is number of genes that control
gene values are less than the control population average and test gene values are greater than
test population average (i.e., vc = 0 & vt = 1), and (iii) c and d are basically the similar notions
(i.e., vc = 1,vt = 0 and vc = 1,vt = 1, respectively).
We define the notion, called a “relationship function”, denoted by f (ti,c j), which signifies
how closely a test sample ti and a control sample c j are related to each other. There could
be many different ways to define this relationship function. Given below are three alternative
functions we tested in our analysis.
1) Odds Ratio (OR) is frequently used to examine the relationship between an exposure and
an outcome, for example, a comparison between the odds that an outcome will occur given a











Here, Odds ratio represents the changing values between control and test sample pairs
with population average. Different forms of contingency tables have been defined in [28].
2) Probability Ratio (PR) is used to examine the changing and remaining between low control
gene expression and high control gene expression. This equation not only points out the rela-
tionship between samples, but also within samples . The probability ratio of control and test is










3) Odds focuses on comparison between genes that change between the control and test sam-





The equation 4.3 presents the conversion ratio of matching control and test. This measure could
be sensitive to the magnitude of input signals. The higher values of Odds, the more DE genes
would be detected.
4.3.2 Finding surrogate control
Next we introduce a measure representing how close two relationships are. For a simplistic
scenario, assume that we are only to choose a surrogate from the available control samples {c j}
with 1 ≤ j ≤ m. For test sample ti without matched control, we find the most ideal surrogate
from c j. We define a distance metric and a surrogate control as following:
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Distance metric:
di j = | f (ti,c j)− f (t j,c j)|(1≤ i≤ n,1≤ j ≤ m)
Surrogates:
Si = {c j|di j ≤ ε,c j ∈C} where ε is some predefined tolerance.
Distance metric is a measure that defines the distance between the values given by a re-
lationship function applied to a pair of control and test samples. Once the function has been
determined, all pairwise distance metrics are computed with the relationship function. Surro-
gates are alternative controls for test samples that do not have matching controls.
Using multiple alternative ratios as the ones introduced in previous part, one can generate
relationship values for all possible pairs of test and control samples. Given all possible pairs,
only the pairs that satisfy the constraint are to be chosen. After enumerating all possible pairs,
only those ones with relationship ratios less than a certain threshold are selected. In each step,
the ratio is computed and compared with nearby neighbors for more fitting with control samples.
Once the ratios exceed the threshold, the algorithm will output the pairs. Otherwise, it will
continue until the last sample is traversed.
When finding all candidate pairs of test and control values, Algorithm 5 generates the
log2 ratio of the test value over the control value. This ratio is later used in any subsequent
meta-analysis of the acquired genome-wide data. In Algorithm 5, control(x) returns matched
normal samples of test sample x if it exists, log2(a,b) computes log2 of the ratio of a to b, and
valuex(y) is the count value of gene x of subject y.
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4.3.3 Pathway score measurement
Designing a methodology that can produce a numeric score which can reliably predict the ag-
gressiveness of cancer cells is not straightforward. Here we introduce our method of calculating
such a score.
56
Algorithm 5 Procedure Find Surrogate Control
Input: a gene set G with the size |G| = p from literacy or experiments of a biological pathway, a cohort threshold ε , p x
(n+m) matrix as read count values of a control set C with |C|= m and a test set T with |T |= n of the gene set G of the cohort.
Output: fold-change values of n test samples of the gene set G using their surrogate control set S.
1. Define a relationship function f (t,c) for a cohort.
2. for g ∈ G
3. for i = 1 to n do
4. if control(ti) = c′ ∈C then
5. valueg(ti)← log2(valueg(ti),valueg(c′))
5. else
6. Si = /0; T [i] = 0;
5. sumg(ti) = 0; avgg(ti) = 0;
6. for j = 1 to m do
7. di j ← | f (ti,c j)− f (t j,c j)|
8. if (di j ≤ ε) then
9. Si← Si +{c j}
10. sumg(ti)← sumg(ti)+ valueg(c j)
11. end if
12. end for
13. avgg(ti)← sumg(ti) / length(Si)
14. valueg(ti)← log2(valueg(ti),avgg(ti))




In this work EMT score is calculated using two major resources: (i) topology of inter-
acting genes and proteins in the form of a gene/protein regulatory pathway, and (ii) statically
meaningful differential expressing (DE) genes obtained by comparing test samples and control
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samples. The key idea behind generating the score is to measure how coherently the biological
activities prescribed in the pathway is calculated when DE genes are compared against the pre-
scribed activities of the EMT pathway. Computing the consistency uses both log2 ratio values
and its corresponding p-value. Since the pathway includes a large number of genes, calculat-
ing the confidence level for the consistency is done through computing a False Discovery Rate
(FDR). Once the EMT score is obtained for each patient sample, the entire cohort of patients
can be grouped based on the score. That is, the cohort of patients are divided into two groups,
one above the chosen threshold and one below the threshold. The former is called the high score
group and the latter the low score group. The next step is to perform the KM survival analysis
to these two subgroups.
4.4 Experimental Results
4.4.1 Data Processing
RNA-seq data of two cancer types, gastric (STAD) and breast (BRCA), were downloaded from
the TCGA public website. Table 4.2 shows the number of samples of these data sets. We
limited our data downloading to RNASeq2 of two types, solid tumor (code 01) for test samples,
and normal/ blood tissue (code 11) for control samples. The corresponding clinical data has
been downloaded from cBioPortal for Cancer Genomics (https://www.cbioportal.org) [29], [30]
which separately maintains clinical data corresponding to each patient whose cancer tissue used
for RNA-seq.
For example, all the data needed for the KM survival analysis such as time in month and
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Table 4.2: The number of case and control samples for each cancer type.
Dataset Case samples Test samples Totals
STAD 415 32 447
BRCA 303 113 416
living/deceased status is available from this data portal site. We filtered out missing values
across all samples. The log2 fold-change values between test and control samples were calcu-
lated, and we prepared two sets of data for our comparative study, that is, one that uses control
population mean and one that uses surrogate controls. Any alias or synonyms were converted
to official gene symbols using our locally developed gene-annotation web service as part of our
data pre-processing.
4.4.2 Matched/unmatched test and control characteristics
In Section 3, we indicated that one can design and explore multiple relationship functions. Our
examples were Odds Ratio (OR), Probability Ratio (PR) and Odds. We point out that a suc-
cessful relationship function should satisfy an important criteria. That is, the function should
produce a uniform relationship measure for all matching test and control pairs but a non-uniform
(e.g., oscillating) relationship measures for unmatched test and control pairs. Figure 4.3 illus-
trates this characteristic of relationship functions. Also included in the figure is the intuition
behind determining surrogate control for test samples without a matched control, which is ex-
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plained shortly.
Fig. 4.3: Three relationship ratios, namely Odds Ratio, Probability Ratio and Odds, respec-
tively, of 32 matched (Top) and unmatched pairs (Bottom) of test and control samples.
Relationship Measure
In Figure 4.3, the X-axis is the matched test sample id (from #1 to #32) and the Y axis is
the value representing the relationship function between the matched test sample and its cor-
responding control sample, i.e., f (ti,ci) where i = {1, . . . ,32}. Figure 4.3 shows the values of
three alternative relationship functions for each f (ti,ci). Odds shows the most uniform distri-
bution of the relationship functions. OR and PR produce very fluctuating plots which indicate
that they may not be a good candidate as a relationship function. Too much fluctuation means
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that the measure is too insensitive with respect to the “compatibility” of the matching test and
control.
Determining the surrogate control
Figure 4.3 shows the case in which one test sample with a matched control , say t30, and 31
unmatched control are compared with the 32 existing control samples f (t30,c1) . . . f (t30,c32).
Again, the measures of all three alternative relationship functions OR, PR and Odds are ploted.
In this figure the middle plot, Odds, reveals candidate surrogate controls for t30 which are en-
closed in a box near Y value of 0.25. The potential surrogate control sample ids revealed by the
Odds plot are 14, 18, 21, 22, 23, 24 and 30. We can pick any of these samples or mean values of
these samples as a surrogate control of t30. This illustration also makes it clear why OR or PR
would not be a good candidate for determining the surrogate control. The bottom half of Figure
4.3 shows that OR and PR measurements (Y values) significantly fluctuate, possibly suggesting
too many “compatibilities” as the surrogate control.
4.4.3 KM survival analysis using surrogate controls
We compared a case of using surrogate controls with the case of using the population average
control to study if the comparison produces any difference.
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Computing EMT score using two alternative methods
The breast cancer data from TCGA includes 416 breast cancer samples with 113 controls and
303 test cases. Of the 303 test cases, 190 test samples do not have matching controls. When
computing the log2 fold-change of each gene expression value between the test sample and the
control sample, we used the surrogate control for each of the 190 test samples using Odds. We
also used the population average of the 113 controls for each gene’s expression value. These
two log2 fold-change data sets were then used to compute respective EMT scores. The former
data set produced 43 high EMT score samples and the latter data set produced 31 high EMT
score samples.
(a) Population average control                                          (b) Surogate control 
Fig. 4.4: Gastric cancer survival plot. The tumor samples were comparing with population-
based average control (a) and surrogate control (b).
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(a) Population average control                                          (b) Surogate control 
Fig. 4.5: Breast cancer survival plot. The tumor samples were comparing with population-
based average control (a) and surrogate control (b).
KM-Plot
The KM survival analyses were performed using the two EMT score lists. Figure 4.4 shows
KM plots using population-based and surrogate control for gastric cancer data (STAD). Figure
4.5 shows the results of a similar analysis done with the breast cancer data (BRCA). KM plot
with surrogates shows a better separation than that of a population average control in breast
cancer and similar separation to the population-based control in gastric cancer. The selected
group with higher EMT scores has a lower survival rate than that of the unselected group.
4.5 Conclusion
A method of imputing subject-specific surrogates for missing controls has been proposed as
an alternative to the conventional method of using population-average. We showed that using
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surrogate controls can indeed improve the analysis outcome by using the publicly available
TCGA data. To our pleasant surprise, our analysis produced an interesting outcome which has
not been reported by the cancer research community. That is, breast cancer patients may also
progress into EMT, as our KM survival analysis clearly demonstrates a poorer prognosis for the
patients with elevated EMT scores. Our analysis also confirmed that the use of subject-specific
surrogate controls produced a poorer prognosis for elevated EMT sub-population for the gastric
cancer case. Unlike the breast cancer case, however, the poorer prognosis for elevated EMT
score for gastric cancer case is also revealed when population average is used and as such fact
is well documented in the gastric cancer research literature. Our conclusion is that the surrogate
control method like ours may be able to discern cases that are too subtle to be detected when
the conventional population average is used.
Chapter 5
BioTarget: a Data Integration Pipeline for Pathway Analysis
5.1 Introduction
Molecular pathway curation includes mostly upstream signals which are well-established in
the literature. However, the functions of downstream target genes of transcription factors (TF)
are awaiting to be studied. We proposed a data mining method to find candidates of TF target
genes for a given molecular pathway. Our goal is to identify the TF target genes and assess
their impacts in the cancer pathways utilizing our integrative data mining models. Specifically,
incorporating multi-resource data into comprehensive models may help biologists explore and
analyze the effects of these targets via pathway analyses. In addition to RNA-seq data, the
number of somatic mutations in individual tumors are depicted to demonstrate the association
between pathway activation and mutation profile of a population. This category of mutation
currently estimates the likelihood of neoantigen formation in different tumor types. Leading
cancer types of this formation are colorectal, stomach, lung adenocarcinoma, and lung squa-
mous. We further explored the function of immunity pathways in these cohorts. The clinical
relevance of T cells in the control of a diverse set of human cancers is now beyond doubt. How-
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ever, the nature of the antigens that allow the immune system to distinguish tumor from regular
somatic cells has long remained obscure. Recent technological innovations have made it possi-
ble to dissect the immune response to patient-specific neoantigens that arise as a consequence
of tumor-specific mutations, and emerging data suggest that recognition of such neoantigens is
a major factor in the activity of clinical immunotherapies [31], [32]. Details of Th1/Th2 Cell
Differentiation pathways can be found in Figure 5.1.
Enrichment analysis of cancer immunity pathways (e.g., TBX21 mediated Th1 Cell Dif-
ferentiation, GATA3 mediated Th2 Cell Differentiation, and BCL6 mediated Tfh signaling) has
several purposes: 1) To understand how does signal transduce from upstream to downstream tar-
gets of TFs (e.g., TBX21, GATA3, and BCL6), 2) whether our proposed model, which utilizes
the pathway structure with explored target genes and/or experimental pathways, can effectively
score the determination of poor prognosis for cancer patients in survival analysis and 3) whether
our model can predict enriched target genes and significance for these signaling pathways. To
assess the pathway significance, we build a scoring system via custom regression and clustering
techniques on target gene set and TCGA RNA-seq expression data for multiple cohorts.
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Fig. 5.1: A: Effector T-cell differentiation Th1, Th2 and other T cells. Th1/Th2 balancing re-
flected in corresponding pathways can promote immune system against cancer. Other
effectors are T-fh, Th17, and T-reg with transcription factors of BCL6, RORγt, and
FOXP3, respectively. B: Pathway visualization of information flow from upstream to
downstream of Th1 and Th2 Cell Differentiation pathways. Main components (tran-
scription factors, effector cytokines, chemokine receptors, and T-cell functions) are
presented in cell differentiation process. Transcription factors (TFs) are TBX21 and
GATA3, respectively. The target genes of these TFs will be identified by the model
which integrates transcriptome and ChIP-seq data.
The study is conducted as follows: 1) ChIP-seq data is processed to annotate nearby
peaks of pre-defined TFs, which were captured during their binding process to potential tar-
get genes using a library (e.g., GRCh38) or from ENCODE transcription factor targets dataset,
2) Customized pathway which have the original upstream, TF, downstream with identified target
genes, and biological process are generated by utilizing linear regression method for each type
of cancer, 3) Based on a pathway score, we perform enrichment analysis to assess the signifi-
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cance of pathway and divide into certain groups of patients that responded better with clinical
prognosis and 4) Validation with associated clinical data is very important to achieve overall
assessment for determining “poor prognosis” cancer patients. Potential target gene set was built
by three main approaches. First, to perform a peak annotation program for DNA binding site
profiles the ChIP-seq data of various cell lines. Second, we adopt the existing target gene set of
similar cell lines. Finally, conducting from the list of target genes is considered when searching
for related literature surveys. The work flow details will be described in Figure 5.2 in Section
5.3.
The outcomes of the BioTarget tool are context-dependent target gene sets, pathway sig-
nificance with these targets and collective scores indicating its activeness. KM survival analysis
and mutation profile of each cancer cohort are to validate the model. Our result shows that
cancer related pathways derived via our scoring system can predict poor prognosis for most
of the cohorts. The putative target genes can be a part of our interest as there are not enough
well-established experimental sets in the domain. An effect score needs to be assigned to a bi-
ological process in the pathway. Note that, there may be multiple scores with their correspond-
ing interpretation of roles. Moreover, in upstream part of Th1 Cell Differentiation pathway
in Figure 5.1, STAT1 and STAT4 are highly correlated with TBX21 in five cancer popula-
tions. The details are stomach (STAD) CorSTAT 1 = 0.53 & CorSTAT 4 = 0.75, breast (BRCA)
CorSTAT 1 = 0.52 & CorSTAT 4 = 0.75, colorectal (COAD) CorSTAT 1 = 0.52 & CorSTAT 4 = 0.6,
lung adenocarcinoma (LUAD) CorSTAT 1 = 0.58 & CorSTAT 4 = 0.55, and lung squamous cell
carcinoma (LUSC) CorSTAT 1 = 0.56 & CorSTAT 4 = 0.68. These high correlation coefficients
give us a hint that upstream of STAT1 and STAT4 has a great impact on TBX21 before transfer-
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ring the signal to downstream TF targets, then to biological process in Th1 Cell Differentiation.
The rest of the chapter is organized as follows. In Section 5.2, we present related works of
using functional pathway analysis to assess pathway significance. In Section 5.3, we provide the
basics of processing data and computational methods. In Section 5.4, we describe the details
of modification of pathway and how to access pathway significance in overall analysis. Two
pathways will be considered as their importance in cancer immunology (Th1 and Th2). We also
discuss other T cells like BCL6 meditated T-fh signaling. Section 5.5 is the conclusion.
5.2 Related Works
Regulatory targets of transcription factors (TF) in pathways have been identified and addressed
in both experiments and in computation throughout the domain of cancer genomics with var-
ious cancer types. As reviewed by Darnell et al. (2002) [33] and Norton et al. (2004) [34],
TFs have played important roles in cancer therapy and other biological processes. Qian et al.
(2005) built an application to retina-specific gene regulation [35]. Ailan et al. (2009) showed
the method to identify target genes of TF activator protein 2 gamma in breast cancer [36]. Cen-
sus of human TFs, such as function, expression and evolution were discussed by Vaquerizas et
al. (2009) [37]. TBX21 mediated Th1 Cell Differentiation, GATA3 mediated Th2 Cell Differ-
entiation, and BCL6 mediated Tfh signaling pathways are schematic representations and have
different activities in cancer immunology. We are interested in exploring binding sites of TFs
on downstream targets in these pathways (Dang et al. 1999 [38], Wang et al. 2013 [39]).
Due to the success of cellular immunotherapies, TBX21, GATA3 and BCL6 mediated
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signaling pathways working toward the cellular migrations of Th1 and Th2 have become popu-
lar in cancer treatment. The cellular immunotherapies against cancer require the generation of
activated CD4+ and CD8+ T-cells. The type of response generated for the Th1 or Th2 cells de-
termines the efficacy of the therapy and it is generally assumed that a type-1 response is needed
for optimal cancer treatment (Terhune et al. 2013 [40], Ivanova et al. 2015 [41]). Furthermore,
CD8+ T cells are known to share certain functional abilities and TFs with other cells of the
immune system. The TBX21 gene, encoding the T-box transcription factor, is a critical target
for both factors with 1 binding early and STAT4 binding later in differentiation. STAT4 and
T-box are required for the expression of many genes in Th1 cells. However, both factors acti-
vate the expression of a subset of genes correlated to Th1 differentiation in the absence of the
other factor. IFNG production, which is the sign of Th1 cells, activates transcription from the
IFNG locus. While IFNG is up-regulated, the reduction of IL4 or IL13 receptors and GATA3
is expected so that Th1 (TBX21) and Th2 (GATA3) both are down-regulated. This process also
involved STAT4, TBX21, and other TFs (e.g., Hlx1 and Runx3) (Best et al. 2013 [42], Gourh
et al. 2009 [43], Pham et al. 2013 [44]).
More information can be found in the research of Lee et al. (2004) relating to gene ex-
pression profiles during human CD4+ T cell differentiation [45]. Predicting gene expression in
the T cell differentiation from histone modifications and TF binding affinities by linear mixture
models are described by Costa et al. (2011) [46]. Cell type-specific DNA methylation at in-
tragenic CpG islands in the immune system is presented by Deaton et al. (2011) [47]. Similar
to Th1 Cell Differentiation pathway, a signaling pathway (namely BCL6 pathway) with main
TF of BCL6 and biological process of Th1/Th2 Cell Migration had been identified by Saito et
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al. (2007) [48]. This activity suppresses BCL6 expression in normal GC B cells and is blocked
in a subset of DLBCL due to alterations in the BCL6 gene. The transcription factors TBX21
and GATA3 control alternative pathways of T-cell differentiation. Resulting in a shared set of
target genes supports our idea of having cell-specific pathways with a common set of targets as
core genes are presented by Jenner et al. (2009) [49]. Kasushik et al. (2017) created Altered
Pathway Analyzer tool to identify differentially regulated and network rewired pathways [50].
In our BioTarget tool, information about activation and inhibition mechanisms from KEGG and
other sources for upstream part has been added for TCGA database to visualize in our pathway
editor. The tool not only identified the target genes of TFs, but also, characterize and prioritize
each pathway for clustering the population that responded better with cancer prognosis.
We use ChIP-seq binding sites of TF and a data mining technique to develop this TF
target prediction tool. Chromatin immunoprecipitation (ChIP) followed by DNA sequencing
(ChIP-seq) and ChIP followed by genome tiling array analysis (ChIP-chip) have become preva-
lent high-throughput technologies for identifying the binding sites of DNA-binding proteins. A
number of algorithms have been proposed to facilitate the identification of the genome-wide
binding sites of the DNA-binding proteins of interest. The identified binding sites as the list
of peaks are usually converted to BED for further processing (Zhu et al. 2010 [51]). The gene
set can be enriched in gene ontology (GO) where genes are associated with some ontologies
(Botstein et al. 2000 [52]). Irreproducible Discovery Rate was used in ENCODE to score rank-
ings for better prediction. In addition, three current approaches in functional pathway analysis
are over-representation analysis, functional class scoring and pathway topology (Khatri et al.
2012 [53], Hoang et al. 2017 [54]). In pathway topology, differentiated genes or gene-level
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statistics are used to determine the components of a pathway topology, which includes num-
bers of reactions, position of gene and type of reaction. Pathway impact factors were obtained
from pathway topology based models. We proposed a method based on the pathway topology
approach with identification of target genes of TF in the downstream to analyze the impact of
these target genes in pathway analysis. A scoring system will be added to evaluate the overall
assessment of the pathway (e.g., activated or inhibited) by taking into account data (e.g., RNA-
seq and somatic mutations). Computationally finding target genes could affect the pathway
analysis. Therefore, we used Kplan-Meier survival analysis to validate the model and target
gene set. Ideally, the scoring system for pathway impact factor is a way of reporting cancer
progress and how far it has been developed. Furthermore, it can be used to grade cancer, or the
similarities between pathways in cancer cells and in normal cells at the tissue-level.
5.3 Material and Method
5.3.1 Data processing of potential target genes from ChIP-seq
Irreproducible Discovery Rate (IDR) was used to measure consistency between replicates in
high-throughput experiments [55]. Also, it uses quality metric and filtering method in score
rankings between peaks in each replicate to determine an optimal cutoff for significance. This
can further be useful for ChIP-seq which we are mainly using to finalize potential target genes.
Optimal and conservative IDR peak sets are chosen for data processing to determine whether
there is a significant overlap between them. These sets are used in annotation process as de-







































Fig. 5.2: A: ChIP-seq experiments with 2kb upstream distance from transcription start site is
considered to have high probability of directed target genes of transcription factor
of TBX21 and others in different cell lines. B: Pipeline for identifying target genes
with the outcome of up-regulated and down-regulated genes in a pathway structure.
The significance of the pathway will be validated by KM survival analysis and other
enrichment analyses.
Figure 5.2 describes the work flow of identification of potential target genes as well as in-
troducing the function pathway analysis. In Part A of Figure 5.2, we utilized ChIPpeakAnno, a
Bioconductor package, to facilitate the batch annotation of the peaks identified from ChIP-seq or
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ChIP-chip experiments of a transcription factor (Zhu et al. 2010 [51]). The package was lever-
aged to annotate binding site peaks to gene names using human assembly reference GRCh38.
To understand whether identified peaks are enriched around the transcription factor which are
likely to be direct target genes, we implemented an application utilizing ChIPpeakAnno to find
the nearest genes. Therefore, we are choosing “2kb” distance from binding site to starting point
of gene in the DNA sequence; namely “upstream” region of the target gene, including exon,
miRNA or other custom features supplied by using the most conserved elements and other tran-
scription factor binding sites [56]. Since the genome annotation gets updated frequently, the
reference library has leveraged to retrieve the annotation data. Different sets of peaks were
collected with multiple thresholded schemes. Two schemes are based on IDR which measures
consistency between replicates. Optimal and conservative IDR sets for each transcription fac-
tor are sets of genes which were annotated with corresponding thresholded peaks. Two sets of
peaks are conservative IDR thresholded peaks and optimal IDR thresholded peaks. The anno-
tated target genes were given by intersection of two sets to form overlapped set. TBX21 has












PTGs of key transcription factors in immune cell development
STAT1 – K562
(n = 313)
Fig. 5.3: Potential target genes of key transcription factors adopted from Smale et al. 2014 in
immune cell development by using two sets from ENCODE. Great overlapped parts
across multiple cell lines of tumor (K562 colon cancer and HepG2 liver cancer) and
normal (B-Lymphocyte cells GM12878).
Various cell lines in ChIP-seq experiments from the ENCODE project was used for iden-
tifying potential target genes of transcription factors [55]. These cell lines are GM12878 im-
mortalised of B-Lymphocyte, MCF-7 breast cancer, HepG2 human liver cancer, and K562 im-
mortalised myelogenous leukemia. The experiments for key transcription factors in immune
cell development can be found in Figure 5.3. Although, the selection of target genes depends
on the choice of ChIP target prediction, the choice of target gene set can be extended gradually
by merging with target lists from literature surveys. We also analyzed multiple target genes of
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transcription factors in pathways such as FOXO3 [57], GATA3 [58]. The rest of potential target
genes of TFs from ENCODE project in Table 6.1.
Table 5.1: Available sets of upstream and target genes of 15 transcription factors from EN-
CODE ChIP-seq datasets and other sources.
ID Transcription factor #Potential target genes Pathway involved
1 BCL6 2882 BCL6
2 CREB1 420 MAPK
3 CREBBP 1625 Wnt
4 FOS 648 MAPK
5 FOXO3 197 MAPK
6 GATA3 355 Th2 Cell Differentiation
7 IRF5 414 Toll-like receptor
8 MYC 198 MAPK
9 PAX5 1130 Transcriptional misregulation in cancer
10 SPI1 125 Transcriptional misregulation in cancer
11 STAT1 313 Th1, Th2, and Th17 cell differentiation
12 STAT2 250 Jak-STAT
13 TBX21 1278 Th1 Cell Differentiation
14 TCF7 274 Wnt
15 TCFL2 389 Wnt
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5.3.2 Pathway significance by scoring system
The goal of this part is to assess pathway significance by collecting supporting and consistency
information in the pathway. Subsequently, a critical task is to examine if a transcription factor
(TF) correlated with other genes, specifically, potential target genes which has been found in
Section 5.3.1. Typically a transcription factor f will be greatly correlated or associated with
many genes, say T ( f ), but finding which genes in T ( f ) are truly downstream targets of f is
not trivial (Nakamura et al. 2016 [59]). By combining potential candidates of target genes
and correlated genes at once in an enrichment analysis, we expect to obtain some f ′s enriched
downstream targets with respect to known or newly discovered functions of genes. Scores for
a pathway with one route are different from ones with multiple routes in the pathway. There
are two main measures, namely route-based propagation (R) and effecting measure scores (M)
as mentioned in Figure 5.2, for each recognizable route and biological process. The goal of
R is identifying which particular route(s) could be in charge for the transcriptome expression
level change of TFs while the value of M could be an estimate of the pathway strength working
functionality (through a biological process) or not.
R jrP = (
∑
k
i=1 I(gT F,i, jr > 0)−∑ki=1 I(gT F,i, jr < 0)
n jr









In Equation 5.1, for each route of an Object i, ∑ki=1 I(gT F,i, jr > 0) is the total number of genes
which have the same signs while ∑ki=1 I(gT F,i, jr < 0) is the total number of genes which have
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opposite signs with T F expression values. n jr is the number of genes in the route. A route is
traversing from T F backward to ligands or the beginning of it. tp is a pre-defined threshold
for p-value. ∑ki=1 I(pi jr < tp) is the total number of genes which have low p-values given a
threshold. The targets of transcription factors were identified in Figure 5.2 needed to enrich
with biological meaning or working tightly with transcription factor which they are regulated
by and with biological process which they are stimulating in a pathway. A scoring scheme with
linear regression is used to seek for gene-gene association and gene-process association. In Th1
Cell Differentiation pathway in Figure 5.4, the route IFNG→ IL12RB2→ JAK2→ STAT 4→
T BX21 is identified as responsible for over expression of TBX21 but there are multiple other
routes leading to TBX21, for example, IFNG → IL12RB2 → TY K2 → STAT 4 → T BX21.
We are using route-based scoring schemes for upstream and downstream in a pathway and
relationship between two genes is considered throughout the pathway [54], [60]. There are two
schemes for each measure: 1) Direction-oriented scoring scheme for upstream and downstream
in a pathway and 2) Route-based scoring schemes for upstream and downstream in a pathway















Similar to R in Equation 5.1, for each route of Object i, ∑ki=1 I(gBP,i, jm > 0) is the total number
of genes which have the same signs while ∑ki=1 I(gBP,i, jm < 0) is the total number of genes which
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have opposite signs with expected values of BP. BP is estimated by the signal of T F . n jm is the
number of genes in downstream part. A route is traversing from BP backward to T F through
up-regulated genes and down-regulated genes of downstream targets. Equation 5.1 for R and
Equation 5.2 for M, both scores are leveraging to biological process evaluation.
The procedure for identification of enriched target genes based on R and M scores of a
pathway is described in below Algorithm.
Additionally, we introduce weights to address statistical issue. The weights are to adjust
the gene expression fold-change values between tumor and control samples. After Step 5, gene





), calculate target gene weights (W r) which indicates the distance from origin to the
regression line of (T F,gi) scatter plot. This is one time calculation per cohort C. In addition,
after Step 6, we can compute Wp or cohort-gene weight as personal weight based on p-value of
each person/ gene compared with the whole cohort C for gene. This is real-time computation
depending on the choice of subcohort C′. The option of Spearman correlation is also available
in BioTarget pipeline.
In Table 5.5, CorC′ is the correlation of R and M scores of a given route for a sub-cohort
which was used for finding associated genes. CorC is the correlation of R and M scores for
the entire cohort. Each row is representing an experiment of a cohort with its size, thresholds,
number of target genes and correlations of Th1 Cell Differentiation pathway.
When the procedure is completed, each pathway (e.g., Th1 Cell Differentiation or Th2
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Algorithm 6 Procedure Get Associated Genes
Get all possible target genes of transcription factors (G′ = {Gu,Gd}) and the extension pathway
P′.
Input: Upstream pathway P, cohort C, target gene set G
Output: Extension pathway P′, possible target gene set G′ for the cohort
1. Generate R score: generate R jP in Equation 5.1.
2. Choose cohort: From R jP, choose cohort Cu with up-thresholded tcu and cohort Cd with down threshold tcu
Cu: high R(P,C), Cu = {C j | R(P,C j)> tcu}
Cd : low R(P,C), Cd = {C j | R(P,C j)> tcd}
C′ =Cu ∪Cd
3. Compute Pearson correlation coefficients: Given target gene set G and transcript factor T F included in the pathway
P, compute Pearson correlation coefficient (r). Different thresholding strategy can be applied, customized, quantile or
absolute.
r(G,Cu,Cd ,T F)→ Gu,Gd Gu: high r(G,Cu,Cd ,T F) Gd : low r(G,Cu,Cd ,T F)
For selected cohort C′ (C′ =Cu ∪Cd ), and given Transcription Factor (TF), a target gene set (G) from literacy or experi-
ments, calculate Pearson correlation coefficients (r) between T F(gT F ) and each target gene (gi).
ri(gT F ,gi,C′) =
∑
nC′
j=1 (gi j− ¯gi j)(gT F, j− ¯ )gT F, j)√
∑
nC′




j=1 (gT F, j− ¯gT F, j 2)
4. Select Subsets of Genes: Select subset Gu of G such that ri(gT F ,gi,C′) is larger than up-gene threshold (tgu) and subset
Gd of G such that ri(gT F ,gi,C′) is smaller than down-gene threshold (tgd ).
Gu = {Gi | ri(gT F ,gi,C′)> tgu} Gd = {Gi | ri(gT F ,gi,C′)< tgd } G
′ = Gu ∪Gd
5. Update pathway: With Gu and Gd update pathway P into P′.
6. Compute M scores: compute Equation 5.2 to obtain MP′ .
7. Filtering outlier: up-regulated and down-regulated genes are pruned out based on statistical-level p-value with respect to
TFs or any genes involving in upstream.
8. Survival analysis: Visualize Kaplan-Meier survival plot and draw scatter plot of R and M scores for cohort C and sub-
cohort C′.
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Table 5.2: Th1 Cell Differentiation pathway with transcription factor TBX21 experiments.
Study Cohort Size Thresholds Numbers of Genes Correlation
ID Name C C’ Gu Gd #Gu #Gd CorC’ CorC
STAD Stomach Adenocarcinoma 414 183 0.7 -0.3 30 17 0.787 0.657
BRCA Breast Carcinoma 1101 642 0.7 -0.5 22 7 0.824 0.718
COAD Colorectal Adenocarcinoma 614 332 0.7 -0.3 4 17 0.743 0.522
LUAD Lung Adenocarcinoma 507 175 0.4 -0.3 10 5 0.78 0.584
LUSC Lung Squamous Cell Carcinoma 490 195 0.7 -0.3 35 11 0.661 0.493
Cell Differentiation pathway) for a study will be added target genes and further used for survival
analysis and enrichment analysis. Five studies are gastric, lung adenocarcinoma, lung squamous
cell carcinoma, breast and colorectal cancer. As mentioned in Section 5.1, subsets of Gu and
Gd are substituted for the target genes in downstream of the original pathway. This could help
biologists explore new pathways or modify existing pathways. They are tailoring to a specific
cancer whereas limited vivo experiments have been done relating to target genes of TFs. The
recursion step of Algorithm 6 is helping for better refining of target genes in tailored pathways.
5.3.3 Statistical significance by density estimation
We used p-value based on density estimation and False Discovery Rate (FDR) to make sure
that the patterns of consistency and connection between genes are considerable compared with
others. When pathway scores are computed, the significance of the patterns will be acquired by
two steps. First, distributions of each gene were obtained, then, the next step is to combine them
into multiple hypothesis tests to produce p-value and FDR values. FDR is used to have control
assessment on multiple testing under dependency of route-based genes and gene regulatory
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[61]. The model requires RNA-seq fold change (e.g., cancer/non-cancer ratio) data from a
large cohorts of patients. FDR values will be derived from a hundreds of samples from TCGA
cancer cohorts. To find real pathway patterns, we assess each patient Pk’s (k = 1 : t where t is
number of patients in a cohort) mRNA values for considering target genes (D1 ∼Dn,U1 ∼Um),
and calculate corresponding p-values and their FDR. Di is down-regulated gene i and U j is
up-regulated gene j of target gene f . We will utilize the non-cancer patient’ mRNA expression
values (population) for calculating p-values and FDR. If non-cancer patients’ mRNA expression
values are not provided, each data will be compared with population data as explained in Section
5.3.2.
The p-value is a probability that the observed data point (sample) is how different from
the data set of null hypothesis H0 (population) [62]. It is calculated as the total area of the
probability density function (pdf) of H0 beyond the observed data point. If Y is a random
variable of observation and y is an actual observed data point, p-value is Pr(Y ≥ y |H0),Pr(Y ≤
y | H0), or 2×min(Pr(Y ≥ y | H0),Pr(Y ≤ y | H0)) in the case of up-regulated genes, down-
regulated genes, up/down regulated genes, respectively.
A pdf of the considering gene’s mRNA expression ratio values of non-cancer patients is
a normalized histogram of the ratios. It can be used as is when the size of the population is
big enough, otherwise Parzen-Window pdf Estimation (PWPE) will be applied to estimate a
smoother pdf. PWPE essentially superposes the same kernel functions which are placed at each
observation. In this way, each observation contributes to estimating the pdf. The kernel function
we are going to use is normalized Gaussian kernel, which has unity total area. The estimated




h ), where K(.) is normalized Gaussian
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kernel, and h is a bandwidth. Higher h will estimate a smoother pdf.
Because the behaviors of considering target genes are known (up- or down-regulated),
we can select one of three p-value formulas with observed data point of that gene expression
value of a cancer patient Pi. For example, for target genes of TBX21 in STAD, D1 (ITGA1) is
supposed to be a Repression gene, we use Pr(Y ≤ y | H0) to calculate the p-value. U2 (CD48)
is supposed to be an Activation gene, therefore we use Pr(Y ≥ y | H0) to calculate the p-value.
If all target genes (D1 ∼Dn,U1 ∼Um) p-values are calculated for a cancer object P1, repeat this
for the rest of patients in the cohort (P2 ∼ Pt).
FDR is then a measure for what portion of the data could be false. FDR can be calculated
using group of p-values of genes that are selected as agreeing genes for each cancer-object Pi.
The calculated FDR of a patient Pi represents that among the highly differentiated p-value genes
(genes with p-value ≥ threshold), FDR portion is probably falsely differentiated p-values. For
example, out of 16 p-values, 15 are less than threshold (ex, 0.01), then FDR is 0.0107, which
means that about 1% of 15 p-values less than the threshold may not be less than threshold. Out
of the selected agreeing genes, Ak× (1−FDR) will be a number of consistent and significant
genes. Measure Mk of patient Pk is calculated as Mk = Ak × 1−FDRn+m , where n and m are the
number of down-genes, and up-genes, respectively. Mi ranges from -1 to 1 (see Step 6 for M
measures).
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5.3.4 Enriched target gene set of transcription factors in T-cell differentiation
Th1 Cell Differentiation target genes
In Table 5.5, CorC′ is the correlation of R and M scores of a given route for a sub-cohort which
was used for finding associated genes. CorC is the correlation of R and M scores for the entire
cohort. Details of number of genes in each experiment are described in Table 5.5.
In the experiment, 1275 potential target genes of TBX21 are processed by using ChIP-seq
data from ENCODE in Section 5.3.1. The customized thresholding scheme is applied. The
target genes of TBX21 in Th1 Cell Differentiation pathway will be reported. Known function
of some genes and newly discover genes were characterized into separated columns for further
analysis.
Moreover, the set is greatly associated with other biological processes in multiple cancer
types. For example, for down-regulated genes, CYP51A1 has been involved in cell viability and
EGFR degradation in colorectal, breast, head and neck, and non-small cell lung cancers [88].
Moreover, EIF4B in RNA processing, protein biosynthesis and ACTR1B in Cytoskeleton were
explored in ovarian cancer [89]. GSTA4 is in cell proliferation, migration and invasion in liver
cancer, breast cancer, prostate cancer and colorectal carcinoma [90]. MAZ is in tumor-specific
expression in breast cancer [91]. In addition, the relation of CD family and SLAM family
function is already provably strong in literature. The structure of CDs helps to enhance T cell
activation by Yan et al. 2007 [66]. Target genes of transcription factor TBX21 can be found
elsewhere. Wang et al. 2015 indicate that Tim-3 expression on NK cells is regulated by Th1,
and that Tim-3 levels correlate with advanced stages of gastric cancer [92]. Studies in mouse
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show that TBX21 protein is a Th1 cell-specific transcription factor that controls the expression
of IFNG. Expression of the human ortholog also correlates with IFNG expression in Th1 and
natural killer cells, suggesting a role for this gene in initiating Th1 lineage development from
naive Th precursor cells [provided by RefSeq, Jul 2008]. Runx3 and T-box proteins cooperate
to establish the transcriptional program of effector CTLs (Cruz et al. 2009 [93]). Transcription
factor Th1 regulates inflammatory arthritis through its function in dendrite cells (Wang et al.
2006 [94]). Details of TBX21 target genes will be discussed in coming section.
Th2 Cell Differentiation target genes
GATA3 target genes were identified by the pipeline with starting number of potential target
genes of 355 mentioned in Section 5.3.1. The absolute thresholding scheme were applied (e.g.,
cut-off threshold of -0.3/0.3 for negative/positive correlation between GATA3 and a target gene).
Below table is representing target genes of transcription factor GATA3 in Th2 Cell Differentia-
tion pathway.
5.3.5 Pathway visualization to improve comprehensibility
The goal of this part is to demonstrate how to incorporate heuristic method into a visualization
tool to control pathway components. Each pathway could combine multiple pathways and can
exponentially grow unless the complexity of the network is controlled. The existing web-based
interactive gene network programs are powerful but do not address the data reduction issue such
as PCViz by Cerami et al. 2010 [104], GeneMania by Warde et al. 2010 [105].
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TCGA-E2-A1LH-01
Th1 activated, Th2 suppressed
TCGA-BH-A1EV-01
Th1 suppressed, Th2 suppressed
Clinical 
data
 Age      59              Status  LIVING
 Gender F                   Stage   I
 Type     BRCA           Time    106.67
 Age       45      Status  DECEASED
 Gender F            Stage   IIIA
























Fig. 5.4: Data visualization of simplified Th1 Cell Differentiation pathway of two patients in
different stages of breast cancer. A typical pathway includes multiple components
including ligands, receptor, kinase, transcription factors, target genes, and biologi-
cal process as mentioned in Figure 5.1B. The pathway components have values from
RNA-seq fold changes at a time, estimates from upstream and downstream signals.
Clinical and other information of subjects have been added to examine the model.
The magnitude of values will be estimated in the model to have better assessment for
these pathway signals.
In Figure 5.1 and Figure 5.4, upstream of Th1/Th2 Cell Differentiation pathway is a com-
bined diagram which is created by literature and other sources such as KEGG and WikiPath-
ways. RNA-seq transcriptome data of each gene is sprayed in the diagram. Two extreme cases
of Th1/Th2 Cell Differentiation have been selected. Clinical data shows the great association
of pathway with the prognosis. The mapping process from transcriptome data of all genes of
each patient and component names (in the pathways) has been completed. Our approach was to
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introduce a set of data reduction heuristics for vast majority of data reduction which is followed
by minimal user rendering of displayed objects (particularly the layout). Pathway visualization
is helping us to acquire comprehensibility effectively. In Figure 5.4, the signals of Th1 and Th2
Cell Differentiation are greatly associated with clinical data as the result will be shown in the
previous section. Patient with ID of TCGA-E2-A1LH clearly has Th1 activated and Th2 sup-
pressed with all target genes work consistently to support the concept. In contradiction, patient
with ID of TCGA-BH-A1EV has both Th1/Th2 suppressed with poor prognosis as a result.
When coordinating a transcriptome profile of patient with respect to the context of a cancer
cohort and target genes of TFs, scientists can validate the result of target genes and how they
interact with TFs and other components in the pathways with transcriptional targets.
5.3.6 Significance test for tailored pathway against decoy pathways
BioTarget demonstrated here is a pipelined bioinformatics system that allows scientists to de-
velop a small number of testable Up/Down target genes of immune resposne pathways, specif-
ically Th1 and Th2 differentiation, in which the role of respective transcription factor TBX21
and GATA3 is fairly firmly established. Generating the small number of target genes is like dis-
tilling or enriching from raw materials (ENCODE ChIP targets in our case identified for TBX21
and GATA3) into a small number which demonstrated strong correlation with the upstream sig-
nals known in Th1/Th2 differentiation pathways. One way to demonstrate the significance of
our gene set reduction process is to calculate the statistical significance of output genes. We
carried out a decoy pathway analysis, an approach which is similar to what has been done in
PARADIGM [106]. In case of Th1 Cell Differentiation pathway which has been extended with
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Up/Down targets, a decoy pathway is created by replacing each gene included in the pathway
with a randomly selected one while the relationships established in the pathway are kept identi-
cal. Total ten random decoy pathways were created to test against tailored pathway of Th1 Cell
Differentiation (Th1*). We used statistical tests with different criteria, which include TTest,
Wilcoxin ranked sum test for difference, and correlation. The outcome of this significance test
is summarized in Table 5.4. We have a “significant” result if at least 2 of 3 criteria are sta-
tistically significant. For example, Random1 and Th1* (score distributions) relation has TTest
and Wilcoxin p-values of 6.90E-13 and 6.42E-14, both are significant, correlation coefficient is
0.14. It means that these two probability distributions clearly have dissimilarity. In Table 5.4,
we have all “significant” results.
5.4 Result and Discussion
5.4.1 Th1/Th2 balancing reflected in corresponding pathways
The aim of this section is to analyze the functional perturbations of applying target genes in
TBX21/GATA3 mediated Th1/Th2 cell differentiation pathways. Targeting Th1/Th2 individu-
ally and collectively as in Th1/Th2 balance will have great impact on assessment of immune
response in each cancer cohort. Firstly, to the TBX21 pathway, there are three possible routes
that can be responsible for gene expression level of Th1. Five studies were used for the enrich-
ment analysis. Experiment details are described in Table 5.5. In Table 5.8, the result for breast
cancer tailored pathway is presented. The KM p-values by M are much smaller compared to the
KM p-values by R. Note that, the survival analysis based on R scores is using the original path-
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way while the survival analysis based on M scores is using the extended pathway. Each cancer
type has different thresholds for its gene profile. β is the threshold in the experiment. All scores
are computed for upstream and downstream paths in the pathway. Based on each score, a cohort
patients will be divided into two groups. The first group has scores greater than the threshold
while other group has lower scores. The following classification scheme was applied. If the
estimated line is far on the top of the total line, it is considered as “good” prognosis, otherwise,
it is “poor” prognosis. KM p-value is to measure what the difference between good and poor
prognosis is in terms of overall status and time (in months).
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Fig. 5.5: A: Correlation of downstream and upstream in Th1 Cell Differentiation pathway (*)
and correlation of transcription factor TBX21 and a target gene CD48 of TBX21 iden-
tified by our approach in breast cancer cohort. B: BRCA breast cancer cohort survival
analysis for tailored Th1 Cell Differentiation pathway. C: Cohort-based study for Th1
Cell Differentiation pathway. When five studies are considered, the extended pathways
by adding target genes performed better in four cohorts (excluding lung adenocarci-
noma LUAD) for the Th1 Cell Differentiation pathway (p < 0.05).
In Table 5.5, each row is representing an experiment of a cohort with its size, thresholds, num-
ber of target genes and correlations of Th1 Cell Differentiation pathway. In Figure 5.5, two
adjacent columns (e.g., STAD-R and STAD-M) are corresponded to a cohort. They show all
KM p-values of a cohort for all thresholds from -1 to 1 before (using R measure) and after
applying targets of TF (using M measure). When five studies are considered, p-values of the
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survival analysis which uses extended pathways (added target genes) are better in four cohorts









Stage 1 Stage 2 Stage 3 Stage 4
P-value = 9.8e-02 P-value = 2.9e-02 P-value = 8.1e-02 P-value = 6.9e-05
P-value = 2.6e-01 P-value = 1.8e-04 P-value = 3.2e-01 P-value = 2.1e-04
KM survival analysis for Th1/Th2 balance in STAD and COAD by stages
Fig. 5.6: A: Overlapping of up-regulated and down-regulated in five cohorts which generally
have high antigen levels in T cells. There is no overlapping among all of them in
both up- and down- regulated genes. Highly overlapping of up-regulated genes in
STAD, BRCA, and COAD was detected as 87 target genes in common. B: Box-plot
for M scores of three cohorts. M is ranging from -1 to 1. C: KM survival analysis for
pathway using these 87 genes.
When fixing the threshold of correlation at 0.3 and -0.3 for five cohorts, we have col-
lected the up-regulated and down-regulated target genes. Note that these five cohorts generally
have high antigen levels in T cells. There is no overlapping among all of them in both up-
regulated and down-regulated genes. However, there are 87 overlapping target genes in STAD,
BRCA, and COAD. Figure 5.6 describes the details of result in this experiment. Significant
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sub-grouping results in three cohorts have been shown in survival plots at the bottom of the
figure. In BRCA and COAD, both cancer types have a great separation between low and high
score groups, however, the trend of each cancer type is different. While BRCA patients with
high Th1 signal have a good survival rate, the opposite trend has been observed in COAD.
The phenomenon suggests a new approach for deeply looking into context-dependent transcrip-
tional targets of TBX21 in corresponding pathway to have proper behavior in supporting the
prognosis.
Th2 Cell Differentiation pathway
The function of Th2 cells is to suppress inflammatory. Recent study from Lozano et al. 2013
showed that CD226 and its ligand CD155 interaction regulated Th1/Th2 balance in the growth
of T cells [95]. Another study showed that CD247 and CD226 play crucial roles in signaling
of lymphocytes [107]. Figure 5.7A show great correlation between GATA3 and its target genes
(e.g., CD226 and CD247) in STAD and COAD. When five studies (STAD, BRCA, COAD,
LUAD, and LUSC) are considered, the extended pathways by adding target genes performed
better in three cohorts (STAD, BRCA, and LUAD) for the Th2 Cell Differentiation pathway.
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Fig. 5.7: Cohort-based study for Th2 Cell Differentiation pathway.
Th1/Th2 balancing in survival analysis
In general, cell population in immune system designed to protect the body from disease and
infection. Therefore, Th1/Th2 Cell Differentiation processes have played important roles to
fight against cancer. However, when it comes to cancer, the mechanism becomes complicated
that may be harmful for the body. Overactivation of either pathway Th1/Th2 can be harmful if
it is fail to meet the set criteria [108]. Yoshino et al. show that the Th2-dominant signal may
cause serious problems in patients with advanced cancer [109]. The immune system even fails
to detect cancer. As a result, the tumors escaped and grew in the body. Immune system can
lose the interaction or become malfunction to fight cancer [110]. To understand the mechanism,
the survival analysis on multiple cohorts (STAD, BRCA, COAD, LUAD, and LUSC) has been
acquired. Figure 5.8 demonstrates the result of sub-grouping in these cohorts. The sub-grouping
clearly suggests that the survival rate is highly associated with the combination of Th1/Th2
signaling pathway with very low p-values. The patients with high Th1 and low Th2 have better
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prognosis in STAD, BRCA [111], and LUAD. In COAD [112] and LUSC, immune system
failed to see cancer. The patients with low signals in both Th1 and Th2 have good prognosis
while high Th1 and low Th2 patients have bad prognosis.
KM survival analysis for Th1/Th2 balance in multiple cohorts
BRCASTAD COAD
LUAD LUSC


























Fig. 5.8: M-based survival analysis. Th1/Th2 balancing reflected in corresponding immunity
pathways (e.g., Th1 Cell Differentiation and Th2 Cell Differentiation). Co-working
effort of Th1 and Th2 cells are to eliminate tumor cells translation, which reduces eva-
sion effects of these cells. In addition, patients with highly activated immune pathways
have a better survival rate. The survival analysis has great p-values of sub-grouping
for each cohort (p < 0.02).
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Majority of patients fall into category of low Th1/Th2 ratio that is reasonable in cancerous
environment in most of cohorts. Surprisingly, in STAD, in squared box, low signal in both Th1
and Th2 have better prognosis compared with both high signal. Incorporating with the stages
of cancer, we find that majority of low Th1/Th2 patients are in early stages (combined Stage 1
and 2 - 60%) while the second group is in later stages (combined Stage 3 and 4 - 63%). We call
this scenario as “imbalance of stages”. Curiously, in COAD, either high signal in Th1 or Th2
worsen the survival rate. The imbalance of Th1/Th2 has crucial impact on prognosis of patients.
No imbalance of stages in this cohort was found (early stages or later stages). BRCA, LUAD,
and LUSC have most of patients in early stages (82.5%, 76%, and 80%, respectively). Two
lung cancers (LUAD and LUSC) have similar behaviors in this analysis. Figure 5.8B shows the
improvement of M-based survival analysis compared with the one using R scores. More details
about the analysis based on stages of cancer will be discussed in next section.
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Fig. 5.9: Th1/Th2 balancing reflected in corresponding immunity pathways (e.g., Th1 Cell Dif-
ferentiation and Th2 Cell Differentiation) with respect to the stages of cancer in STAD
and COAD. Same color coding was applied as in Figure 5.8.
In Figure 5.9, we demonstrate Th1/Th2 balance by observing the progression of cancer.
There are four recognizable stages of cancers from 1 to 4 [113]. Each stage has different phe-
nomenon of genotype data. STAD and COAD are chosen to rationalize stage-based survival
analysis. In STAD, from Stage 1 to 4, the group of high signal of both Th1 and Th2 clearly
moved from the position of bad prognosis to good prognosis. Patients in this group is predicted
to have good immune response as in Th1/Th2 balance to help fighting against cancer. The Stage
4 p-value of STAD is really significant (p< 0.0001). In COAD, imbalance of Th1/Th2 carry out
at all four stages when having strong indication at Stage 2 and Stage 4 (p < 0.0002). It clearly
shows that immune response is not sufficient for COAD patients of this particular group to be
treated [114], [115]. Other immunotherapy treatments may be essential. In summary, the exper-
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iments point out that immune response of Th1, Th2, combined and individual is very important
in cancer immunotherapy. Depending on the cancer type and a cohort context, transcriptional
targets of TFs in corresponding pathways have strong contribution to predict and characterize
the needs of individuals and groups in cancer treatment.
5.4.2 Mediating downregulation signal of BCL6 pathway
BCL6 is a transcriptional repressor and also considered as a critical regulator of geminal centers
where B cells are selected on production of antibodies with high affinity for the antigens [116].
BCL6 pathway was formed using upstream path including IFNG, JAK, and STAT. Upstream
path of transcription factor BCL6 is adopted from Park et al. 2014 [117] and downstream path
with target genes such as STAT, GATA, CCR, NFKB1 . . . that works towards biological process
of Th1/Th2 Signaling and T Cell migration is migrated from Hatzi et al. 2015 [118]. We used
β = 0 thresholded classes for this experimental pathway. Figure 5.10B shows the experiment
for LUAD cohort. Note that, red line is for R > 0 group and green line is for R < 0 group.
Similarly, M > 0 and M < 0 are for red/green groups, respectively. The group of patients with
downregulation signal of BCL6 pathway has worse prognosis compared with the group who
does not. P-value = 0.0016 is very small that suggests a critical impact of transcription factor of
BCL6 of T-fh cells and its target genes in immune system while working against cancer.
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B- BCL6 pathway score based survival plot for LUAD
P-value = 4.7e-01 P-value = 1.6e-03
Total (511)
R > 0 (344)
R < 0 (167)
Total (511)
M > 0 (14)

















Based on M scoresBased on R scores
Fig. 5.10: A: Pathway Visualization of BCL6 pathway. B: Survival analysis based on the path-
way scores for Lung Adenocarcinoma cancer with R and M thresholded at zero (e.g.,
R > 0 vs. R < 0 and M > 0 vs. M < 0). C - Cohort-based study for BCL6
pathway. Most of the studies have KM p-values smaller of M compared with R. The
distribution is shifted to bottom. The extended pathway outperforms the original one
of all five cohorts in KM survival analysis.
Each row presents an experiment on BCL6 mediated T-fh signaling pathway of a cohort.
Similarly to the previous section of Th1/Th2, two adjacent columns are corresponded to a cohort
to compare KM p-values of survival analysis before and after adding target gene set into the
pathway. N = 10 is total of data columns. KM p-values for M score are heading to zero
(statistical significance) while KM p-values for R score are floating near one (not statistical
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significance). Most of the studies have KM p-values smaller of M compared with R. The box
plot in Figure 5.10 is shifted to bottom. Survival analysis of the extended pathway outperforms
the original one of all five cohorts.
5.4.3 Tumor-specific mutated target genes
Mutation drivers of immunological responses to cancer hinge upon the leading mutation types
[119]. Missense mutations in tumor suppressors are highly associated with functionality of
pathway [120]. Leading types are gastric, colorectal, lung, and breast cancers [31]. Mutation
data distribution using R looks as same as that is using M in gastric and colorectal cancers.
Mutation data distribution using R looks different than that is using M in breast cancer.
We have identified the target genes which have widely upstream DNA sequence that is
nearby the binding sites of TFs. Next step is to resolve the cross-talks of functionality between
these TFs, we need to predict the impact ei for each T Fi and combine signals by referencing
to TF expression levels or DNA methylation. This could help to know whether actual loci
has been methylated by which T Fi. However, binding sites could be in multiple loci to cause
context-dependent target gene expression as mentioned by Nakamura et al. 2016 [59].
5.5 Conclusion
Extracting the data from multiple resources and incorporating them into a comprehensive tool
could help biologists to explore and analyze the roles of target genes of transcription factors in
a molecular pathway. Cancer signaling pathways are analyzed using BioTarget to understand
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Signal Transduction and its impact on target genes to induce specific biological processes. Our
results show improved ability to identify poor prognosis of cancer patients. Our scoring system
quantifies pathway activation, that can later be used to classify patients for KM survival analysis.
Specifically, we demonstrated KM results in three pathways, Th1 Cell Differentiation, Th2
Cell Differentiation, and BCL6 pathways. Depending on the choice of cut-off thresholds, this
number could further increase in our data mining model. Subsequently, we analyzed the signifi-
cance of such pathway extension by utilizing KM survival analysis. In terms of survival analysis
results, several pathways (mainly Th1/Th2 Cell Differentiation and BCL6 pathways) have qual-
itatively better performance with the proposed extension. These results are also consistent with
the pathway association enrichment study and are validated with previously reported literature
for various cancer cohorts. Many mutated genes and their leading types for each cohort are also
reported in this chapter.
Overall, Th1/Th2 balance in T-cell differentiation is considered as crucial marker to pre-
dict the survival rate of patients based on the choice of transcriptional target genes. BLC6
mediating downregulation is also added to make the signals clearer for better understanding
of immune responses. Survival analysis in this study suggests that immune responses are cor-
respondent to the target genes of TFs in pathways. The question is that how much they are
associated with each other in cancer immunotherapy. This raises the context of cancerous envi-
ronment of differentiation of T cells to suppress tumor growth and metastases. The picture will
be clearer when we analyze additional relevant cellular processes such as Cell Proliferation and
Apoptosis.
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Table 5.3: Target genes of transcription factor TBX21 in Th1 Cell Differentiation pathway.
Study Up/Down genes and their functionality
STAD Up: APOBEC3H [63], ARHGAP30 [64], CCL4 [65], CD48 [66], CD53 [66], CORO1A [67], CRTAM
[68], CXCR3 [69], FCRL6 [70] GPR171 [71], GPR65 [72], GRAP2 [45], GZMK [73], HCLS1 [74],
HCST [75], IFNG, IL18RAP [76], IL21R [77], ITGAL [76], KLHL6, LAX1, LSP1, LY9, NKG7,
P2RY10, PDCD1LG2 [78], SLAMF8 [66], SLFN12L, TBC1D10C, TRIM22
Down: CDCA7L [79], COG3, CSNK2A1, CSTF1, F11R, FARSB, FLAD1, GSTA4, HUS1, NLK,
PIGV, SLC3A2, SPATA17 [80], TAF2, TBRG4, TSTD1, ZDHHC6
BRCA Up: AGAP2, CD28 [66], CD48 [66], CD53 [66], FCRL3 [81], FCRL6 [82], GPR171 [71], GPR183,
GRAP2 [81], HCLS1, IL18RAP [76], IL23R, LAX1, LRMP, LY9, MS4A1 [83], NKG7 [84],
PDCD1LG2, SLC9A9 [85], SLFN12L, SRGN, TBC1D10C
Down: ARFIP2, BTRC, COPB1 [86], KBTBD4, SPATA17 [80], TSTD1, TTC26 [?]
COAD Up: IL21R [77], ITGAL [76], NKG7, TBC1D10C
Down: AARSD1, COX17, F11R, LYSMD1, MACC1, MRPL9, PON2, RNF43, RPL12, RPL14,
RPL23, RPL5, RPS18, SMG7, SNRPE, TARS2, ZNF774
LUAD Up: ARHGAP30 [64], CCL4 [65], CD48 [66], CORO1A [67], CRTAM, CXCR3, FCRL3, FCRL6
[70], GRAP2 [87], GZMK, IFNG, IL18RAP [76], ITGAL [66], NKG7, TBC1D10C
Down: BYSL, COPB1 [86], DHRS13, ELL3, GSPT1, ILF2, LYSMD1, MRPS18B, NDUFS1, PEMT,
PEX13, PPP1R11, PTS, SEC23B, SLC35B2, SLC39A7, SNRPE, TSG101, TSTD1, VPS52
LUSC Up: ARHGAP30, CCL4, CD28 [66], CD48 [66], CD53 [66], CD86 [66], CIITA, CORO1A [67], CR-
TAM, CTSS, CXCR3 [69], FCRL3, FCRL6 [70], GPR171 [71], GPR65, GPSM3, GRAP2, GZMK,
HCST, IL18RAP [76], IL21R [77], ITGAL [76], ITGB7, LAIR1, MNDA, NKG7, P2RY10, PIK3CG,
PTPN22, SELPLG, SLAMF8 [66], SLC15A3, TBC1D10C, ZBP1, ZC3H12D
Down: ACTL6A, COPS2, DDX18, ERAL1, GSTA4, METTL2A, MRPL30, PAK1IP1, PDCD10,
PHF5A, SLC35F5
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Study Up/Down genes and their functionality
STAD Up: CAMK2D, CD226 [95], CD247 [66], GNA15 [96], HIVEP2, IKZF3, IL18R1 [76], IL2RB [76],
ITK, MAP3K5, TRAD
Down: PRKCH, RASGRP1, RASSF5, SEMA4D [97], SMAP2, SPEF
BRCA Up: ARHGAP26 [98], ARV1, ASB2, ATXN10 [99], AXIN2 [100], BCAT2, BLCAP, CAMK2D,
CBLB, CCDC12, CD226, CD247 [66], CDK5RAP2, CHEK2, CHL1, CRB2, CX3CR1, EIF3D,
ETV5, FAM124B, FAM3C, FOXP1, GNA15, HINT1, HSCB, IKZF3, IL13, IL18R1, IL2RB [101],
IRF9, ITK, LSM4, MAP3K5, MED29, MOBP, MYL12B, MYL6B, NHSL2, NOL3, NSMCE1,
POLR3GL, PPP3CA, RASGRP4, RASSF5, ST8SIA1, STK40, TCF3, TGFBR3, TMEM131,
TMEM134, TRADD, TULP2, UNKL, XIRP1, ZDHHC24, ZFP36, ZNRF
Down: ZFPM1, AEBP2, AGPAT5 [102], ANK1, ASAP1, ATN1, BZRAP1, CCDC146, CCDC88C,
CCR6, CDK8, CEP68, CHD3, CISH, CRB3, FANCC, FBXL8, HIVEP2, HSF4 IFT20, IGF1R
LRRC6, LYRM7, MAP2K4, MAPK6, MAPKAPK3, PRKCH, RAD50, RALGAPB, RASGRP1,
NUCB1, PAF1, PAQR8, PDE3B, PELI1, RNF31, RORA, RPS6KA2, SBF2, SLC25A23, SMAD7,
SPEF2 SRPK1 TNFAIP1, TTC13, RGS2, RNF220, RNLS, RPL11, RYR1, SEMA4D, SERPING1,
SMAD3 [103], SMAP2, SPINT1, TTLL11, WDFY2, WDR60, WHSC1L
COAD Up: ANK1, CAMK2D, CBLB, CHD3, FAM124B, HIVEP2, MAP3K5, NHSL2,POLR3GL,
PPP3CA, RASGRP4, RGS2, RPS6KA - Down: BZRAP1, CDK8, CHEK2, HSF4, MAPKAPK
LUAD Up: ASB2, CAMK2D, CCR6, CD226, CD247, IL18R1, IL2RB [101], ITK, MAP3K5, NHSL2,
PRKCH, RASGRP1, RASGRP4, RASSF5, RYR1, SEMA4D, SERPING1, ST8SIA1 WDFY - Down:
CCDC12, LSM4, MED29, MYL6B, PAF1, CX3CR1, FAM124B, GNA15,IKZF3,IL13,RNF22
LUSC Up: ARHGAP26 [98], CAMK2D, CCDC88C, CCR6, CD226 [95], IL2RB [101], ITK, PPP3CA,
PRKCH, RASGRP1, RASGRP4, RASSF5, SERPING1, SMAD7, SMAP2, XIRP
Down: AGPAT5 [102],ETV5,HINT1, HSCB, MOBP, CD247, CISH, GNA15 HIVEP2, IKZF3,
MYL6B, RNF220, SRPK
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Table 5.4: Significant tests for Th1 Cell Differentiation decoy pathways (Random i) and a tai-
lored pathway for gastric cancer cohort (Th1*).
Pathway scores TTest Wilcoxin Correlation
Random1 and Th1* 6.90E-13 6.42E-14 0.14
Random2 and Th1* 1.98E-26 2.95E-23 0.17
Random3 and Th1* 4.43E-18 5.87E-19 0.07
Random4 and Th1* 3.68E-05 1.36E-06 0.34
Random5 and Th1* 4.48E-21 9.67E-20 0.19
Random6 and Th1* 1.87E-22 2.11E-21 0.11
Random7 and Th1* 7.81E-33 9.94E-27 0.01
Random8 and Th1* 1.01E-25 6.65E-23 0.23
Random9 and Th1* 1.51E-10 8.21E-11 0.02
Random10 and Th1* 3.19E-20 2.63E-22 0.26
Table 5.5: Th1 Cell Differentiation pathway experiments.
Cohort Size Thresholds Numbers of Genes Correlation
Study C C′ Gu Gd #Gu #Gd CorC′ CorC
STAD 414 183 0.7 -0.3 30 17 0.787 0.657
BRCA 1101 642 0.7 -0.5 22 7 0.824 0.718
COAD 614 332 0.7 -0.3 4 17 0.743 0.522
LUAD 507 175 0.4 -0.3 10 5 0.78 0.584
LUSC 490 195 0.7 -0.3 35 11 0.661 0.493
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Table 5.6: R-based and M-based survival analysis in Th1/Th2 balance.






Table 5.7: BCL6 pathway scores based survival analysis.
Study Threshold β KM P-value by R KM P-value by M
STAD 0 4.7e-1 6.1e-02
BRCA -0.5 3.4e-3 1.4e-3
COAD -0.2 2.2e-2 3.9e-4
LUAD 0 4.7e-1 1.6e-3
LUSC 0.5 6.9e-1 2.6e-1
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Table 5.8: Th1 Cell Differentiation pathway scores associated with mutation profile within a
group and between two groups (activated and inhibited pathway-cohorts).
Study Highly mutated genes Leading mutation type
STAD
LRP1B, SYNE1, OBSCN, CSMD3,






PIK3CA, MUC16, UNC13C, MAP3K1,
DMD, NLRP7, PKHD1, SPTA1,
GOLGA6L2, WDFY3, DNAH11
missense, frame shift ins
frame shift del, nonsense
LUAD
RYR2, USH2A, ZFHX4. SPTA1,





TP53, CSMD3, ZFHX4, FYR3,





CD53, JAK2, SLC9A9, CLECL1,
MACC1, TCP11L2, RNF43, ZBP1
TSHZ2, STAT1, ZFYVE26, CLEC7A
nonsense & silent
Chapter 6
Pathway Analysis of Cell Proliferation Incorporating Cell Differentiation
6.1 Introduction
Tumor formation and progression can occur through defects both within and outside cancer
cells, changing their normal functions in signaling pathways (e.g., proliferation, differentiation,
migration, and other processes). Pathways are complex with multiple entities (e.g., ligand, re-
ceptor, enhancer, transcription factor, and biological process) and their associated cross-talks.
Upstream regulators in a pathway, which are well-established, may act by promoting or dis-
rupting some inter- and intramolecular interactions and carry their signals downstream. In the
Kyoto Encyclopedia of Genes and Genomes (KEGG), a well-known pathway database, down-
stream targets of transcription factors in the pathway are not fully annotated. To understand
the overall architecture of the signaling pathway, all these target genes are ultimately needed to
identify, predict, and further explore the impacts of them on the biological process of a pathway
. The present study explores the target genes of TFs in three molecular cell proliferation path-
ways (TCF7, TCF7L2, and LEF1 in Wnt; CREB1, MYC, JUN, and FOS in MAPK; STAT3 in
IGF). These TFs are known for their roles in tumor cell proliferation and immunosuppression.
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However, we can use BioTarget to explore the oncogenic functions of TFs by identifying their
target genes under specific micro-environments.
Wnt signaling is generally a context-dependent pathway, which relies on the presence or
absence of Wnt ligands. When there are no signals from Wnt ligands, a destruction complex
composed of Axin-1 and its tumor suppressor partners (including APC, GSK3B, and CK1) is
formed. The destruction complex phosphorylates β -catenin and targets proteasomal degrada-
tion regulating the cytoplasmic level of β -catenin. Otherwise, they bind to the Frizzled/Lrp5/6
receptor, which leads to the phosphorylation of a negative regulator of the destruction complex,
called Disheveled (Dvl). Dvl engages Axin, and inhibits its interaction with other components
of the destruction complex. Then, β -catenin is free to gather the cytoplasm and transfer to the
nucleus, where it activates the transcription of Wnt target genes (Duchartre et al., 2016 [121];
Stamos et al., 2013 [122]). These target genes regulate the biological processes of cell prolifera-
tion, stem cell development (e.g., CD44 and Lgr5), and tumorigenesis (e.g., CmyC and Cynclin
D1).
The MAPK pathway is a key regulator in numerous tissue types and contributes to many
types of cancer. The pathway is responsive to the family of receptor tyrosine kinases known as
the EGF receptors. These include HER2, a receptor known to be amplified in breast cancers
(Nancy and Gwen [123]). The BRAF V600E variant in melanoma is a mutation of this pathway,
which causes the constitutive activation of RAF in the kinase cascade. This mutation overex-
presses the proliferation function of cells, resulting in melanoma. The ERK1/2 transcription
factor activates the transcription of genes related to apoptosis, proliferation, and tumorigenesis.
Three genes downstream of ERK1/2 that are directly related to cancer progression and prog-
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nosis include CREB, MYC, and FOS. CREB and FOS are activated by members of the RSK
family, which are phosphorylated by ERK1/2 [124]. CREB (cAMP response element binding
protein) acts as a master regulator downstream of cAMP. CREB has in upward of 5,000 target
genes, some of which are known to serve a role in cell survival and proliferation. Moreover,
CREB upregulation has been found to contribute to poor prognosis in acute myeloid and lym-
phoid leukemia. In such cases, CREB facilitates S phase entry in cell cycling and allows for
growth factor-independent cell cycling [125]. FOS binds to the JUN protein to form the AP-1
heterodimer. JUN can dimerize with multiple proteins, but when FOS and JUN bind they can
contribute to tumor progression. AP-1 activates proliferation as a transcription factor. The pro-
tein dimer also suppresses tumor suppressor genes via DNA methylation, removing regulatory
functions in cells. AP-1 activates angiogenesis, the process in which blood vessels are formed
around a tumor to provide nutrients necessary for growth. The complex is also found to activate
tumor invasion, leading to metastatic progression [126]. MYC is directly activated by ERK1/2,
and is amplified in cancers. Chromosome translocations that hyper-activate MYC are consis-
tent in Burkitt lymphoma and multiple myeloma. In addition, malfunctioning of the WNT/APC
pathway that results in MYC upregulation is common in colorectal cancer. Furthermore, MYC
has been found to reprogram fibroblasts into pluripotent stem cells [127]. These three tran-
scription factors are tied to prognoses in cancers, and can be used to evaluate disease across
numerous tissues since all are tied to conserved cellular regulatory pathways. However, targets
will differ within tissues for these transcription factors, resulting in unique disease phenotypes.
Organ development, growth, and survival are dependent upon signaling from the insulin-
like growth factors (IGFs), which promote cell proliferation and suppress apoptosis. As a result,
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IGF signaling is also implicated in tumor growth, cancer progression, and metastasis. A recent
effort has been put forward in targeting different components of the IGF signaling pathway for
the development of novel cancer therapies. IGFs are natural growth hormones produced by the
liver, and include IGF1, IGF2, and insulin. They exert their cellular effects by binding to the
insulin-like growth factor receptor (IGF-1R) on the surface of cells, which triggers a cascade of
downstream cellular events that subsequently lead to changes in gene transcription. Following
ligand binding, IGF-1R becomes activated via tyrosine phosphorylation of its β subunits, and
adaptor proteins IRS-1, IRS-2, and Shc are recruited. Subsequently, both the PI3K/AKT and
RAS/MAPK pathways also become activated . The PI3K/AKT arm of the downstream pathway
exerts anti-apoptotic effects by inhibiting the FOXO family of transcription factors and upregu-
lating anti-apoptotic proteins such as BCL-2 and NFkB. Glucose metabolism is also upregulated
via GSK-3β activity to provide energy for cellular growth. The RAS/MAPK arm of the down-
stream pathway exerts mitogenic effects by upregulating the transcription factors ELK1 and
STAT3 (Zhang et al., 2006 [128]; Zha and Lackner, 2010 [129]). Alterations to the expression
or function of IGF-1R have been linked to the development of cancer, and increased levels of
IGF-1R have been observed in melanoma, breast cancer, and pancreatic adenocarcinomas. Sev-
eral attempts have been made to antagonize IGF-1R as a mechanism to treat cancer. Increased
levels of the ligands IGF1 and IGF2 have also been connected to increased risk of breast, lung,
colon, and prostate cancers. Higher levels of IGFs facilitate more rapid proliferation of tumor
cells, and their inhibition is also an attractive target for cancer treatment (Brahmkhatri et al.,
2015 [130]).
For this case study, we decided to examine a relationship between the activation of one
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arm in the IGF -1R pathway and the consequences of this on transcription factor activation and
the up- or downregulation of target genes in various cancer types. Utilizing STAT3 as a tran-
scription factor for separation significantly distinguishes two patient cohorts that have increased
or decreased gastric cancer survival rates. STAT3 target genes were identified as relevant to can-
cer immunology [131]. STAT3 is well-known for its role in tumor cell proliferation, survival,
invasion, and immunosuppression. STAT3 also promotes cancer through inflammation, obesity,








































A – Cell proliferation and differentiation B – Multiple functions of STAT3
 
Fig. 6.1: A: Difference between cell proliferation and cell differentiation processes. B: Multiple
functions of STAT3 in different microenvironment. STAT3 dual functions are in tumor
cells and immune microenvironment. Oncogenic function of STAT3 can lead to cancer
progression due to enhanced tumor aggressive and immune invasion
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6.1.1 Related Works
ChIP-seq binding sites and the accompanying transcriptome data of RNA-seq have been used
for to explore the target genes of transcription factors (TF) in multiple pathways. In a ChIP-seq
experiment, controlling many cellular processes requires the coordinated activation or repres-
sion of genes in the correct spatial and temporal patterns. Such regulation is performed by TFs
binding to DNA sequences within chromatin, and activation or repression of the transcription
of nearby genes. This binding is frequently sequence-specific, where the sequence is recog-
nized by the TF itself or by other related proteins. The initial step in identifying targets of a
TF usually involves the overexpression or knockdown of the factor in question, followed by an
analysis of subsequent changes in gene expression. The development of microarray technol-
ogy has facilitated this type of analysis, allowing the identification of numerous downstream
genes, which was previously perceived as infeasible. However, this method does not provide
information regarding whether targets are directly regulated by the TF through binding to reg-
ulatory sequences within the gene, or whether regulation is indirect and facilitated through the
activation of intermediate genes (Taverner et al., 2004 [132]).
The regulatory targets of TFs in pathways have been identified and addressed in both
experiments and computation throughout the domain of cancer genomics. Notably, Darnell et
al. (2002) demonstrated that TFs act as targets for cancer therapy [33]. Furthermore, Qian
et al. (2005) built an application for retina-specific gene regulation [35]. Breast cancer cells
have been thought to identify target genes of TF activator protein 2 gamma [36]. A census of
human TFs including their function, expression, and evolution was provided by Vaquerizas et
al. (2009) [37]. Wnt/β -catenin, MAPK, and IGF pathways are schematic representations and
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have behaved differently for a specific pathway. Namely, we are interested in exploring the
binding sites of TFs on downstream targets in these pathways. Nakamura et al. (2016) reported
that Wnt target gene expression is tissue- and stage-specific, and is controlled by subsequent
β -catenin targeting downstream biological processes [59].
6.2 Materials and Methods
6.2.1 Identification of target genes
This part is to describe how to identify putative target genes. These target genes were obtained
from multiple cell line experiments from the ENCODE project. We utilized ChIPpeakAnno, a
Bioconductor package, to facilitate batch annotation of the peaks identified from ChIP-seq or
ChIP-chip experiments of a transcription factor (Zhu et al. 2010 [51]). The package was lever-
aged to annotate binding site peaks to gene names using human assembly reference GRCh38. In
order to understand whether identified peaks are enriched around the transcription factors likely
to be direct target genes, we implemented an application utilizing ChIPpeakAnno to locate the
nearest genes. Therefore, we chose a “2kb” distance from the binding site as the starting point
of a gene in the DNA sequence; namely the upstream region of the target gene, including ex-
ons, miRNA, or other custom features supplied by using the most conserved elements and other
transcription factor binding sites [56]. Since genome annotation receives frequent updates, the
reference library was leveraged to retrieve annotation data in real time. Different sets of peaks
were collected with multiple threshold schemes. Two schemes were based on IDR, which mea-
sures consistency between replicates. Optimal and conservative IDR sets for each transcription
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factor represent sets of genes that were annotated with corresponding thresholded peaks. The
two sets of peaks were conservative IDR thresholded peaks and optimal IDR thresholded peaks.
Annotated target genes were provided by the intersection of the two sets to form an overlapped
set . Various cell lines in ChIP-seq experiments from the ENCODE project was used for identi-
fying potential target genes of transcription factors [55].
GM 12878 HeLa-S3 MCF_10A_0.01%ethanol
MCF 10A 4-hydroxy-
tamoxifen - 12 hours
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Fig. 6.2: ChIP-seq experiment for target genes of transcription factor STAT3 with multiple cell
lines from ENCODE.
These cell lines are GM12878 immortalized B-Lymphocyte, HeLa-S3, and MCF-10A,
with different treatments. Although the selection of target genes depends on the choice of
ChIP target prediction, the choice of target gene set can be gradually extended by merging with
target lists from the literature. We also analyzed multiple target genes of transcription factors in
pathways such as FOXO3 [57] and GATA3 [58].
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Table 6.1: Available sets of upstream and target genes of proliferation related transcription fac-
tors from ENCODE ChIP-seq datasets and other sources.
ID TF #Potential target genes Pathway involved
1 CREB1 420 MAPK
2 FOS 648 MAPK
3 MYC 198 MAPK
4 MAX 941 MAPK
5 STAT3 1178 IGFβ
6 TCF7 275 Wnt
7 TCFL2 388 Wnt
8 LEF1 369 Wnt
6.2.2 Scoring system and pathway significance
The goal of the present study is to examine if and how TFs correlate with other genes. Typi-
cally, a transcription factor f will be greatly correlated or associated with many genes, though
determining which genes in T ( f ) are actual downstream targets of f is not trivial (Nakamura et
al. 2016 [59]). By combining the potential candidates of target genes and correlated genes in
an enrichment analysis simultaneously, we expect to obtain some of the enriched downstream
targets of f. We provide a scoring system for pathway analysis, where scores can represent a
route or a pathway with multiple routes. Two main measures exist for this purpose, namely
route-based propagation R and effecting measure scores M, for each recognizable route and bi-
ological process. The goal of R is to identify which particular route(s) could be responsible for
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transcriptome expression level change of key marker gene(s), while the value of M can estimate
the strength of the working functionality of a pathway (through a biological process). The detail
can be found in Section 5.3.2.
The targets of transcription factors were identified in Figure 6.3, and were necessary to
enrich with biological meaning or work closely with the transcription factor which they are
regulated by, as well as the biological process which they are stimulating in a pathway. A
scoring scheme with linear regression is used to seek gene-gene association and gene-process
association. In the IGF pathway presented in Figure 6.3, the route IGF1→ IGF1R→GRB2→
HRAS→ MAP2K → STAT 3 is identified as being responsible for overexpression of STAT3.
However, there are multiple alternative routes leading to STAT3; for example, IGF2→ IGF1R→
SHC1→ NRAS→ STAT 3. In the present study, we use route-based scoring schemes for the
upstream and downstream processes in a pathway, and the relationship between two genes is
considered throughout the pathway [60]. FDR was used to control the assessment of multiple
tests under dependency of route-based genes and gene regulatory processes [61].
6.3 Results and Discussion
6.3.1 Cell proliferation in MAPK and Wnt pathways
This section explores Wnt and MAPK signaling by the target genes of their transcription factors.
The Wnt pathway has four TFs in a complex: TCF7, TCF7L1, TCF7L2, and LEF1. Depend-
ing on the impact of each transcription factor on their downstream targets, the activeness of
biological processes can be very different.
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Table 6.2: Wnt pathway experiments.
Cohort Size Thresholds Number of Genes Correlation
Study C C′ Gu Gd #Gu #Gd CorC′ CorC
STAD 414 36 0.4 -0.4 12 3 -0.096 -0.041
BRCA 1101 107 0.4 -0.4 11 9 0.259 0.154
COAD 614 58 0.4 -0.4 11 4 0.062 0.119
OV 296 105 0.3 -0.3 26 7 0.308 0.285
GBM 163 32 0.4 -0.4 7 18 0.452 -0.01
LUAD 507 80 0.4 -0.3 10 5 -0.033 0.038
LUSC 490 67 0.3 -0.3 13 3 0.083 0.065
Enrichment analysis was used to analyze the Wnt pathway in the explored target genes.
The Wnt pathway is divided into two parts: the upstream path from Wnt ligands to TFs, and the
downstream path from TFs to biological processes. At the tissue level, to our best knowledge,
the response is ultimately controlled by a Wnt code that integrates expression patterns and the
various signaling inputs of multiple Wnt ligands.
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Table 6.3: Wnt pathway scores based survival analysis.
Study Threshold β KM P-value by R KM P-value by M
STAD -0.5 2.9e-1 1e-1
BRCA -0.35 9.3e-1 3.4e-2
COAD -0.2 2.2e-2 3.9e-4
OV 0.33 8.9e-1 3.1e-2
GBM 0.21 9.6e-1 7.6e-1
LUAD -0.34 6.6e-1 6.4e-4
LUSC 0.5 7.8e-1 9.3e-2
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TCGA-BR-4256
Age      80              
Status     DECEASED
Gender   MALE                   
Type       STAD
Time       9.33
Fig. 6.3: Data visualization of a simplified IGF pathway for a gastric cancer patient. A typical
pathway includes multiple components, including ligands, receptor, kinase, transcrip-
tion factors, target genes, and biological processes . Pathway components possess
values from RNA-seq fold changes at a given time, which are estimates from up-
stream and downstream signals. Clinical and other information from subjects have
been added to examine the model. The magnitude of values in the model will be
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Class2 (M < -0.4)







LUAD tailored Wnt pathway score based survival plot
Fig. 6.4: Lung Adenocarcinoma tailored pathway scores threshold survival plot before and after
applying target genes in downstream.
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Fig. 6.5: Tailored pathway scores survival plot before and after applying target genes in down-
stream of all cohorts.
Tammela et al. (2017) [133] reported that Wnt pathway activation correlates with poor
survival in human lung adenocarcinoma, but not in human squamous cell lung cancer. Each
score was based an experiment involving a cohort of the Wnt pathway being applied to a column
, and two adjacent columns corresponded to a cohort. The X and Y axis indicate KM P-values
and cohorts with the p-value of KM survival plots before and after the targets of TFs were
applied, respectively. Of the seven studies conducted, extended pathways with added Wnt target
genes performed far better in seven cohorts (excluding gastric and glioblastoma).
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Table 6.4: Survival analysis p-values for cell proliferation in Wnt pathway by singular tran-
scription factor and combining transcription factor targets in COAD.
TF(s) Upstream Downstream Combined
LEF1 7.2e-01 4.7e-01 1e-01
TCF7 7.2e-01 1.4e-02 3.8e-02
TCF7L2 7.2e-01 2.5e-03 3.7e-03
TCF7L2 - TCF7 7.2e-01 4.8e-03 8.2e-03
TCF7 - TCF7L2 7.2e-01 8.7e-03 5.3e-02
TCF7L2 - LEF1 7.2e-01 6.3e-02 2e-01
TCF7 - LEF1 7.2e-01 1.2e-03 5.7e-02
LEF1 - TCF7L2 7.2e-01 4.1e-03 1.1e-02
LEF1 - TCF7 7.2e-01 4.3e-02 1.4e-01
6.3.2 STAT3 activation in Insulin-like Growth Factor pathway
The present study indicated that KIT and KIT ligand are the most important routes of the up-
stream portion. We then proceeded to the target gene identification pipeline, and hypothesized
that MYC is the most critical TF for the downstream portion. Resulting values for R, M, and
RM of COAD were 0.69, 2.40E-06, and 5.50E-03, respectively. When combining MYC and
other TFs such as CREB1 and FOS, a significant outcome was obtained, with KIT, KITLG,
MYC, and their target genes leading the route in the COAD cohort. These target genes include
LMBR1L, FLOT1, TLE6, GADD45B, and GOLGA2 (upregulated), and MBTD1, BCCIP, and
SRFBP1 (downregulated).
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Fig. 6.6: Functional pathway analysis STAT3 in T cells. A dataset of STAT3 target genes were
identified for gastric cancer cohorts, which included 39 upregulated genes and 5 down-
regulated genes. Both histograms of R and M scores (not shown) exhibit a Gaussian
distribution. Through the use of the extended pathway with these target genes, func-
tional pathway analysis was significantly improved from sub-figure A (used RM-based
scores) to sub-figure B (added missense mutation).
A dataset of STAT3 target genes were identified for gastric cancer cohorts, and included
39 upregulated genes and 5 downregulated genes. Histograms for both R and M scores exhibit
a Gaussian distribution. By using the extended pathway with these target genes, functional
pathway analysis improved remarkably where the two groups were well separated. Mutation
profiles of two groups were significantly different when dividing by R and M. The median (Q2)
was used to estimate the division point. Mutation profiles of two groups were significantly
different when dividing by R and M.
Key targets for STAT3 include BCLXL (BCL2L1), an anti-apoptotic; CCND1, pro-cell
cycling; P21wafCip1, a tumor suppressor or oncogene (context-dependent); MYC, pro-cell
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proliferation; and BCL-5 (Survivin), an anti-apoptotic. Significant evidence exists for STAT3
activation of BCL3. Generally, JUNB is upregulated in the cohort. Previous works have high-
lighted the relationship between STAT3 activation, JUNB activation, and the activation of CD30
and ALK both of which are known as oncogenes. On one hand, CD30 is known to deregulate
cell cycling and lead to proliferation in anaplastic large cell lymphoma along with ALK, and
this significant observation has been observed in other cancer types. On the other hand, BCL3
is a non-canonical coactivator of NFKB, and can lead to activation of this pathway. In summary,
in this gastric cohort experiment, STAT3 and JUNB activate the AKT pathway, leading to more
sever cancer, which explains better prognoses observed in STAT3 low cases.
6.3.3 Coordinating cell proliferation and differentiation
The purpose of this section is to determine if STAT3 activation antagonizes the balancing of
Th1/Th2 cell differentiation, and how they are presented in the cell cycle. MAPK and Wnt/β -
catenin pathways are most relevant to reflecting cell proliferation in cancer. Coordinating this
with cell differentiation provides an improved understanding of the cell cycle and additional
impacts that may occur when studying multiple cancer cohorts. MAPK is a master regulatory
cellular pathway, and is involved in cellular regulation of proliferation, apoptosis, and differ-
entiation. MAPK is activated through the binding of ligands to cell surface receptors. These
can be receptor tyrosine kinases or G protein-coupled receptors. Once receptors are activated, a
phosphorylation cascade begins. In the major regulatory arm of the pathway, activated receptors
are scaffolded to other cell surface proteins. RAS is then activated by the receptor complex, and
acts to phosphorylate RAF, which phosphorylates MEK1/2, and then phosphorylates ERK1/2.
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ERK1/2 can further act to regulate gene expression, either directly as a transcription factor, or
by continuing the phosphorylation chain from outside or within the nucleus [134] [135].
Fig. 6.7: Th1 Cell Differentiation pathway signal in combination with Th2 Cell Differentiation
pathway and IGF pathway with transcription factor STAT3. The groups of high-Th1




We have analyzed the activities related to downstream transcription factors (TF) that were not
well-studied by previous research. For example, the downstream targets of TFs are rarely an-
notated in KEGG (a well-known pathway database). This research focused on establishing a
computational method that facilitates the identification of candidate target genes of a transcrip-
tion factor for a given molecular pathway, which can be useful for scientists exploring cancer
treatments. Specifically, we analyzed cell proliferation with Wnt, Mapk, and IGF pathways.
TFs are TCF7/LEF1, MYC, JUN/FOS, and STAT3. They are well-known for their roles in tu-
mor cell proliferation and immunosuppression. In addition to these established aspects as TFs in
cancer, we used BioTarget to explore the target genes of these TFs and their functions in coordi-
nating cell differentiation under specific micro-environments. We discovered that the oncogenic
functions of TFs were predominantly activated in some cancer cohorts. This result provides a
greater understanding of pathway signals in cancer cell proliferation and cell differentiation.
Chapter 7
Conclusion
A data integration tool for pathway analysis must be based on a firm foundation of performance
and biological findings. When designing such a system, the traditional trial-and-error approach
is replaced with one that is much more rigorous via being data- and knowledge-driven. Two
exciting research areas of computational biology and bioinformatics are pathway analysis and
data integration. This line of research will continue on a specific disease by formulating schemes
with biological-finding guarantees and further implementing systems in combination with in
vivo experiments on subjects with the disease. All these areas require intense formalism and/or
implementation so that we can see if they are practical. In summary, the work continues to be
ongoing and additional attention will be needed.
In fact, upstream signals of a molecular pathway are documented in the literature, but
the activities downstream of TFs have not been explored much. Moreover, a key role of these
activities related to target genes of TFs has arisen in cancer signaling pathways. In this thesis,
we developed a computational method capable of determining candidate target genes of a TF
included in a given molecular pathway for better analysis, and the results can later be used in
prognosis and treatment of cancer patients.
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Existing tools for extracting biological meaning from this data have limited capabilities,
although transcriptome data can supply a detailed readout of events taking place during a par-
ticular form cancer. The “BioTarget” tool incorporates ChIP-seq data into cellular pathway
analysis to infer TF activity from RNA-seq data. With this, we have focused on two main
biological processes of cells differentiation and cell proliferation.
With cell differentiation, we evaluated the Th1 and Th2 immune responses in cancers
based on TBX21 and GATA3 pathway activity, respectively. Incorporation of TF activity in
pathway quantification improved patient stratification. As a result, an unbalanced Th1/Th2 re-
sponse correlated with a poorer survival of colon cancer patients whereas low Th1/Th2 activity
ratios were associated with poorer survival of stomach and breast cancer patients. These results
are also consistent with the pathway- association enrichment study and have validated with pre-
viously reported literature for various cancer cohorts. Many mutated genes and their leading
types for each cohort have also reported in this research.
Overall, Th1/Th2 balance in T-cell differentiation is considered as crucial marker to pre-
dict the survival rate of patients based on the choice of transcriptional target genes. Survival
analysis indicates that immune responses are correspondent to the target genes of TFs in path-
ways. The question is how much they are associated with each other in cancer immunotherapy.
This also raises the question of whether the context of the cancerous environment of differen-
tiation of T-cells suppresses tumor growth and metastasis. We also applied BioTarget to BCL6
meditating the T-fh signaling pathway, and patients with higher BCL6 activity had significantly
improved survival rates. In addition, BCL6 is a TF with a less understood impact as it is in-
volved with both T-cells and B-cells.
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The second study is on the biological process of cell proliferation. The analyzed pathways
are Wnt, Mapk and IGF with TFs of TCF7/LEF1, MYC, JUN/FOS and STAT3, respectively.
They are all well-known for their roles in tumor cell proliferation and immunosuppression.
However, when using BioTarget, we observed that the oncogenic functions of TFs were domi-
nantly activated in particular cancer cohorts. This leads to the idea of dual functions of certain
TFs that are mostly new in this domain.
7.1 Summary of Contributions
Gene set comparison is one of the key essential operations that is universally needed in many
high-throughput genomic data analyses. Additionally, a conventional way of comparing one
gene set against a large number of target gene sets is through database programming. However,
this approach can be ineffective when the sizes of the target gene sets become massively large.
We presented a gene identifier encoding scheme which could store a very large number of
gene sets entirely in memory. This coding scheme suggests the feasibility of storing the target
gene sets in memory and using it over and over again for the analysis of the high quantity of
arriving query sets. Our case studies demonstrated our coding scheme could offer linear time
performance proportional to the number of arriving input query sets [136].
We presented a method of extending a protein/gene regulatory pathway into a better one
by eliminating gene regulatory relationships or adding new relationships where these exten-
sions are inferred by analyzing RNA-seq data. We used Conditional Mutual Information with
histogram estimation for the pruning and extension. We applied the method to a gene/protein
regulatory EMT pathway. We evaluated with four types of cancer data sets, gastric, colorectal,
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rectal and breast cancers that are available from the TCGA public web portal. One positive
outcome of our evaluation is that in three out of the four cancer data sets their corresponding
modified/extended pathway produced increased consistency between the regulatory relation-
ships of the EMT pathway and the transcriptome data obtained from RNA-seq. For gastric
cancer, our finding is consistent with what is already known in the literature, that is, severe
EMT cases are often found in gastric cancers. In breast cancer, EMT score may not be a good
measure for cancer prognosis is also consistent with finding of previous studies [54].
A method of imputing subject-specific surrogates for missing controls has been proposed
as an alternative to the conventional method of using population-average. We showed that using
surrogate controls can indeed improve the analysis outcome by using the publicly available
TCGA data. To our pleasant surprise, our analysis produced an interesting outcome which
has not been reported by the cancer research community. That is, breast cancer patients may
also progress into EMT, as our KM survival analysis clearly demonstrates a poorer prognosis
for the patients with elevated EMT scores. Our analysis also confirmed that the use of subject-
specific surrogate controls produced a poorer prognosis for elevated EMT sub-population for the
gastric cancer case. When using the subject-specific surrogate method, the system can suggest
a potential merit for new discoveries, which cannot be revealed if using the population control
[137].
Extracting the data from multiple resources and incorporating them into a comprehensive
tool could help biologists explore and analyze the roles of target genes of transcription factors
in a molecular pathway. Our results show improved ability to identify poor prognosis of cancer
patients. Specifically, we demonstrated KM results in three pathways, Th1 Cell Differentiation,
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Th2 Cell Differentiation, and BCL6 pathways. Depending on the choice of cut-off thresholds,
this number could further increase in our data mining model. Subsequently, we analyzed the
significance of such pathway extension by utilizing KM survival analysis.
In terms of survival analysis results, several pathways (mainly Th1/Th2 Cell Differentia-
tion and BCL6 pathways) have qualitatively better performance with the proposed extension.
These results are also consistent with the pathway association enrichment study and are vali-
dated with previously reported literature for various cancer cohorts. Many mutated genes and
their leading types for each cohort are also reported in this Chapter 5. We also analyzed cell
proliferation with TFs of TCF7, TCF7L2 and LEF1 in Wnt, MYC, JUN and FOS in Mapk,
STAT3 in IGF pathway. They are all well-known for their roles in cell proliferation and im-
munosuppression. In addition to these established aspects as TFs in cancer, we used BioTarget
to “newly” identify target genes of these TFs and explore functions coordinating with cell dif-
ferentiation in different micro-environments. We discovered that oncogenic functions of TFs
were dominantly activated in particular cancer cohorts.
In addition, we performed deep pathway analysis [138] and route-based pathway analysis
[60] using Bayesian network. We proposed a new way of analyzing biological pathways in
which both transcriptome and mutation data are using to identify routes of aberrant pathways.
First, we have demonstrated the effectiveness of our model through simulation to discern pa-
tients in Test group compared with Control group. Second, we applied our model with TCGA
breast cancer data set against some KEGG pathways. Our experiment assured the claims re-
ported from PAM50 as the original breast cancer sub-type study. Our model can also analyze
the patients of each sub-type based on “route” identification. We can find commonly perturbed
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pathway routes for HER2+ patients. Deep pathway analysis could be very useful in finding
cancer treatment.
7.2 Future Work
Although these analyses elicited favorable results, we believe our work can be further improved.
In the future, we can extend it in two ways: 1) a broader set of experimental contexts can be used
in order to examine the performance of additional assessments; and 2) a single-cell TF behavior
can be added to address the issue in cancer pathways. The target prediction can utilize further
information available in Gene Ontology and possibly other resources. We can also obtain a
broader set of experimental contexts, such as multiple cell-line specific data sets, where ChIP-
seq and transcriptome data are amply available from the public domain. In addition, we will
extend biological pathways by including both direct and indirect TF targets as this might assist
us better handle cross-talk in pathways.
Bibliography
[1] N. Siva, “1000 genomes project,” Nature biotechnology, vol. 26, no. 3, pp. 256–256,
2008.
[2] C. G. A. R. Network et al., “Integrated genomic analyses of ovarian carcinoma,” Nature,
vol. 474, no. 7353, pp. 609–615, 2011.
[3] E. P. Consortium et al., “The encode (encyclopedia of dna elements) project,” Science,
vol. 306, no. 5696, pp. 636–640, 2004.
[4] R. Edgar, M. Domrachev, and A. E. Lash, “Gene expression omnibus: Ncbi gene expres-
sion and hybridization array data repository,” Nucleic acids research, vol. 30, no. 1, pp.
207–210, 2002.
[5] D.-G. Shin, S.-H. Hong, P. Joshi, R. Nori, B. Pei, H.-W. Wang, P. Harrington, L. Kuo,
I. Kalajzic, and D. Rowe, “Pbc: A software framework facilitating pattern-based clus-
tering for microarray data analysis,” in Bioinformatics, Systems Biology and Intelligent
Computing, 2009. IJCBS ’09. International Joint Conference on, Aug 2009, pp. 30–36.
[6] P. Joshi, B. Pei, S.-H. Hong, I. Kalajzic, D.-J. Shin, D. Rowe, and D.-G. Shin, “A soft-
ware framework integrating gene expression patterns, binding site analysis and gene on-
tology to hypothesize gene regulation relationships,” in Bioinformatics and Biomedicine
(BIBM), 2013 IEEE International Conference on, Dec 2013, pp. 210–213.
[7] B. Zhang, S. Kirov, and J. Snoddy, “Webgestalt: an integrated system for exploring gene
sets in various biological contexts,” Nucleic acids research, vol. 33, no. suppl 2, pp.
W741–W748, 2005.
[8] A. Gyenesei, J. Moody, C. A. Semple, C. S. Haley, and W.-H. Wei, “High-throughput
analysis of epistasis in genome-wide association studies with biforce,” Bioinformatics,
vol. 28, no. 15, pp. 1957–1964, 2012.
[9] X. Wan, C. Yang, Q. Yang, H. Xue, X. Fan, N. L. Tang, and W. Yu, “Boost: A fast
approach to detecting gene-gene interactions in genome-wide case-control studies,” The
American Journal of Human Genetics, vol. 87, no. 3, pp. 325–340, 2010.
[10] Y. Xi and W. Li, “Bsmap: whole genome bisulfite sequence mapping program,” BMC
bioinformatics, vol. 10, no. 1, p. 232, 2009.
131
132
[11] R. Fan, M. Zhong, S. Wang, Y. Zhang, A. Andrew, M. Karagas, H. Chen, C. Amos,
M. Xiong, and J. Moore, “Entropy-based information gain approaches to detect and to
characterize gene-gene and gene-environment interactions/correlations of complex dis-
eases,” Genetic epidemiology, vol. 35, no. 7, pp. 706–721, 2011.
[12] C. Wu, S. Li, and Y. Cui, “Genetic association studies: an information content perspec-
tive,” Current genomics, vol. 13, no. 7, p. 566, 2012.
[13] C. Kingsford and S. L. Salzberg, “What are decision trees?” Nature biotechnology,
vol. 26, no. 9, pp. 1011–1013, 2008.
[14] K. Wang, D. Singh, Z. Zeng, S. J. Coleman, Y. Huang, G. L. Savich, X. He,
P. Mieczkowski, S. A. Grimm, C. M. Perou et al., “Mapsplice: accurate mapping of
rna-seq reads for splice junction discovery,” Nucleic acids research, vol. 38, no. 18, pp.
e178–e178, 2010.
[15] Z. Wang, M. Gerstein, and M. Snyder, “Rna-seq: a revolutionary tool for transcrip-
tomics,” Nature reviews genetics, vol. 10, no. 1, pp. 57–63, 2009.
[16] T. Z. Tan, Q. H. Miow, Y. Miki, T. Noda, S. Mori, R. Y.-J. Huang, and J. P. Thiery,
“Epithelial-mesenchymal transition spectrum quantification and its efficacy in decipher-
ing survival and drug responses of cancer patients,” EMBO molecular medicine, p.
e201404208, 2014.
[17] G. Xie, A. Ji, Q. Yuan, Z. Jin, Y. Yuan, C. Ren, Z. Guo, Q. Yao, K. Yang, X. Lin et al.,
“Tumour-initiating capacity is independent of epithelial–mesenchymal transition status
in breast cancer cell lines,” British journal of cancer, vol. 110, no. 10, pp. 2514–2523,
2014.
[18] X. Zhang, X.-M. Zhao, K. He, L. Lu, Y. Cao, J. Liu, J.-K. Hao, Z.-P. Liu, and L. Chen,
“Inferring gene regulatory networks from gene expression data by path consistency al-
gorithm based on conditional mutual information,” Bioinformatics, vol. 28, no. 1, pp.
98–104, 2011.
[19] X. Zhou and J. Liu, “Inferring gene dependency network specific to phenotypic alteration
based on gene expression data and clinical information of breast cancer,” PloS one, vol. 9,
no. 3, p. e92023, 2014.
[20] J. C. Marioni, C. E. Mason, S. M. Mane, M. Stephens, and Y. Gilad, “Rna-seq: an
assessment of technical reproducibility and comparison with gene expression arrays,”
Genome research, vol. 18, no. 9, pp. 1509–1517, 2008.
[21] V. Marx, “Cancer genomes: discerning drivers from passengers,” Nature methods,
vol. 11, no. 4, pp. 375–379, 2014.
[22] C. J. Creighton, J. C. Chang, and J. M. Rosen, “Epithelial-mesenchymal transition (emt)
in tumor-initiating cells and its clinical implications in breast cancer,” Journal of mam-
mary gland biology and neoplasia, vol. 15, no. 2, pp. 253–260, 2010.
133
[23] J. W. Song and K. C. Chung, “Observational studies: cohort and case-control studies,”
Plastic and reconstructive surgery, vol. 126, no. 6, p. 2234, 2010.
[24] S. Wacholder, D. T. Silverman, J. K. McLaughlin, and J. S. Mandel, “Selection of con-
trols in case-control studies: Iii. design options,” American journal of epidemiology, vol.
135, no. 9, pp. 1042–1050, 1992.
[25] P. Hu, C. M. Greenwood, and J. Beyene, “Integrative analysis of multiple gene expression
profiles with quality-adjusted effect size models,” BMC bioinformatics, vol. 6, no. 1, p. 1,
2005.
[26] E. A. Stuart and D. B. Rubin, “Matching with multiple control groups with adjustment
for group differences,” Journal of Educational and Behavioral Statistics, vol. 33, no. 3,
pp. 279–306, 2008.
[27] S. le Cessie, N. Nagelkerke, F. R. Rosendaal, K. J. van Stralen, E. R. Pomp, and H. C.
van Houwelingen, “Combining matched and unmatched control groups in case-control
studies,” American journal of epidemiology, vol. 168, no. 10, pp. 1204–1210, 2008.
[28] N. Scotia, “Explaining odds ratios,” J Can Acad Child Adolesc Psychiatry, vol. 19, p.
227, 2010.
[29] E. Cerami, J. Gao, U. Dogrusoz, B. E. Gross, S. O. Sumer, B. A. Aksoy, A. Jacob-
sen, C. J. Byrne, M. L. Heuer, E. Larsson et al., “The cbio cancer genomics portal: an
open platform for exploring multidimensional cancer genomics data,” Cancer discovery,
vol. 2, no. 5, pp. 401–404, 2012.
[30] J. Gao, B. A. Aksoy, U. Dogrusoz, G. Dresdner, B. Gross, S. O. Sumer, Y. Sun, A. Jacob-
sen, R. Sinha, E. Larsson et al., “Integrative analysis of complex cancer genomics and
clinical profiles using the cbioportal,” Science signaling, vol. 6, no. 269, p. pl1, 2013.
[31] T. N. Schumacher and R. D. Schreiber, “Neoantigens in cancer immunotherapy,” Science,
vol. 348, no. 6230, pp. 69–74, 2015.
[32] Y.-C. Lu and P. F. Robbins, “Cancer immunotherapy targeting neoantigens,” in Seminars
in immunology, vol. 28, no. 1. Elsevier, 2016, pp. 22–27.
[33] J. E. Darnell Jr, “Transcription factors as targets for cancer therapy,” Nature reviews.
Cancer, vol. 2, no. 10, p. 740, 2002.
[34] L. Norton, X. Chen, M. Fourcaudot, N. K. Acharya, R. A. DeFronzo, and S. Heikkinen,
“The mechanisms of genome-wide target gene regulation by tcf7l2 in liver cells,” Nucleic
acids research, vol. 42, no. 22, pp. 13 646–13 661, 2014.
[35] J. Qian, N. Esumi, Y. Chen, Q. Wang, I. Chowers, and D. J. Zack, “Identification of
regulatory targets of tissue-specific transcription factors: application to retina-specific
gene regulation,” Nucleic acids research, vol. 33, no. 11, pp. 3479–3491, 2005.
[36] H. Ailan, X. Xiangwen, R. Daolong, G. Lu, D. Xiaofeng, Q. Xi, H. Xingwang, L. Rushi,
Z. Jian, and X. Shuanglin, “Identification of target genes of transcription factor activator
protein 2 gamma in breast cancer cells,” BMC cancer, vol. 9, no. 1, p. 279, 2009.
134
[37] J. M. Vaquerizas, S. K. Kummerfeld, S. A. Teichmann, and N. M. Luscombe, “A cen-
sus of human transcription factors: function, expression and evolution,” Nature reviews.
Genetics, vol. 10, no. 4, p. 252, 2009.
[38] C. V. Dang, “c-myc target genes involved in cell growth, apoptosis, and metabolism,”
Molecular and cellular biology, vol. 19, no. 1, pp. 1–11, 1999.
[39] S. Wang, H. Sun, J. Ma, C. Zang, C. Wang, J. Wang, Q. Tang, C. A. Meyer, Y. Zhang,
and X. S. Liu, “Target analysis by integration of transcriptome and chip-seq data with
beta,” Nature protocols, vol. 8, no. 12, p. 2502, 2013.
[40] J. Terhune, E. Berk, and B. J. Czerniecki, “Dendritic cell-induced th1 and th17 cell dif-
ferentiation for cancer therapy,” Vaccines, vol. 1, no. 4, pp. 527–549, 2013.
[41] E. A. Ivanova and A. N. Orekhov, “T helper lymphocyte subsets and plasticity in autoim-
munity and cancer: an overview,” BioMed research international, vol. 2015, 2015.
[42] J. A. Best, D. A. Blair, J. Knell, E. Yang, V. Mayya, A. Doedens, M. L. Dustin, A. W.
Goldrath, I. G. P. Consortium et al., “Transcriptional insights into the cd8+ t cell response
to infection and memory t cell formation,” Nature immunology, vol. 14, no. 4, pp. 404–
412, 2013.
[43] P. Gourh, S. K. Agarwal, D. Divecha, S. Assassi, G. Paz, R. K. Arora-Singh, J. D.
Reveille, S. Shete, M. D. Mayes, F. C. Arnett et al., “Polymorphisms in tbx21 and stat4
increase the risk of systemic sclerosis: evidence of possible gene–gene interaction and
alterations in th1/th2 cytokines,” Arthritis & Rheumatology, vol. 60, no. 12, pp. 3794–
3806, 2009.
[44] D. Pham, Q. Yu, C. C. Walline, R. Muthukrishnan, J. S. Blum, and M. H. Kaplan, “Op-
posing roles of stat4 and dnmt3a in th1 gene regulation,” The Journal of Immunology,
vol. 191, no. 2, pp. 902–911, 2013.
[45] M. S. Lee, K. Hanspers, C. S. Barker, A. P. Korn, and J. M. McCune, “Gene expression
profiles during human cd4+ t cell differentiation,” International immunology, vol. 16,
no. 8, pp. 1109–1124, 2004.
[46] I. G. Costa, H. G. Roider, T. G. do Rego, and F. d. A. de Carvalho, “Predicting gene
expression in t cell differentiation from histone modifications and transcription factor
binding affinities by linear mixture models,” BMC bioinformatics, vol. 12, no. 1, p. S29,
2011.
[47] A. M. Deaton, S. Webb, A. R. Kerr, R. S. Illingworth, J. Guy, R. Andrews, and A. Bird,
“Cell type–specific dna methylation at intragenic cpg islands in the immune system,”
Genome research, vol. 21, no. 7, pp. 1074–1086, 2011.
[48] M. Saito, J. Gao, K. Basso, Y. Kitagawa, P. M. Smith, G. Bhagat, A. Pernis,
L. Pasqualucci, and R. Dalla-Favera, “A signaling pathway mediating downregulation of
bcl6 in germinal center b cells is blocked by bcl6 gene alterations in b cell lymphoma,”
Cancer cell, vol. 12, no. 3, pp. 280–292, 2007.
135
[49] R. G. Jenner, M. J. Townsend, I. Jackson, K. Sun, R. D. Bouwman, R. A. Young, L. H.
Glimcher, and G. M. Lord, “The transcription factors t-bet and gata-3 control alternative
pathways of t-cell differentiation through a shared set of target genes,” Proceedings of
the National Academy of Sciences, vol. 106, no. 42, pp. 17 876–17 881, 2009.
[50] A. Kaushik, S. Ali, and D. Gupta, “Altered pathway analyzer: A gene expression dataset
analysis tool for identification and prioritization of differentially regulated and network
rewired pathways,” Scientific reports, vol. 7, p. 40450, 2017.
[51] L. J. Zhu, C. Gazin, N. D. Lawson, H. Pagès, S. M. Lin, D. S. Lapointe, and M. R. Green,
“Chippeakanno: a bioconductor package to annotate chip-seq and chip-chip data,” BMC
bioinformatics, vol. 11, no. 1, p. 237, 2010.
[52] D. Botstein, J. M. Cherry, M. Ashburner, C. Ball, J. Blake, H. Butler, A. Davis, K. Dolin-
ski, S. Dwight, J. Eppig et al., “Gene ontology: tool for the unification of biology,” Nat
Genet, vol. 25, no. 1, pp. 25–9, 2000.
[53] P. Khatri, M. Sirota, and A. J. Butte, “Ten years of pathway analysis: current approaches
and outstanding challenges,” PLoS Comput Biol, vol. 8, no. 2, p. e1002375, 2012.
[54] T. H. Hoang, P. Joshi, S.-H. Hong, and D.-G. Shin, “Extending biological pathways by
utilizing conditional mutual information extracted from rna-seq gene expression data,”
in International Conference on the Development of Biomedical Engineering in Vietnam.
Springer, 2017, pp. 151–156.
[55] E. P. Consortium et al., “The encode (encyclopedia of dna elements) project,” Science,
vol. 306, no. 5696, pp. 636–640, 2004.
[56] R. Lister, M. Pelizzola, R. H. Dowen, R. D. Hawkins, G. Hon, J. Tonti-Filippini, J. R.
Nery, L. Lee, Z. Ye, Q.-M. Ngo et al., “Human dna methylomes at base resolution show
widespread epigenomic differences,” nature, vol. 462, no. 7271, p. 315, 2009.
[57] A. Eijkelenboom, M. Mokry, E. De Wit, L. M. Smits, P. E. Polderman, M. H. Van Triest,
R. Van Boxtel, A. Schulze, W. De Laat, E. Cuppen et al., “Genome-wide analysis of
foxo3 mediated transcription regulation through rna polymerase ii profiling,” Molecular
systems biology, vol. 9, no. 1, p. 638, 2013.
[58] G. Wei, B. J. Abraham, R. Yagi, R. Jothi, K. Cui, S. Sharma, L. Narlikar, D. L. Northrup,
Q. Tang, W. E. Paul et al., “Genome-wide analyses of transcription factor gata3-mediated
gene regulation in distinct t cell types,” Immunity, vol. 35, no. 2, pp. 299–311, 2011.
[59] Y. Nakamura, E. de Paiva Alves, G. J. C. Veenstra, and S. Hoppler, “Tissue-and stage-
specific wnt target gene expression is controlled subsequent to β -catenin recruitment to
cis-regulatory modules,” Development, vol. 143, no. 11, pp. 1914–1925, 2016.
[60] Y. Zhao, T. Hoang, P. Joshi, S. Hong, C. Giardina, and D. Shin, “A route-based pathway
analysis framework integrating mutation information and gene expression data.” Methods
(San Diego, Calif.), 2017.
136
[61] Y. Benjamini and D. Yekutieli, “The control of the false discovery rate in multiple testing
under dependency,” Annals of statistics, pp. 1165–1188, 2001.
[62] Y. Hochberg, “A sharper bonferroni procedure for multiple tests of significance,”
Biometrika, vol. 75, no. 4, pp. 800–802, 1988.
[63] N. M. Shaban, K. Shi, K. V. Lauer, M. A. Carpenter, C. M. Richards, D. Salamango,
J. Wang, M. W. Lopresti, S. Banerjee, R. Levin-Klein et al., “The antiviral and cancer
genomic dna deaminase apobec3h is regulated by an rna-mediated dimerization mecha-
nism,” Molecular cell, 2017.
[64] J. Wang, J. Qian, Y. Hu, X. Kong, H. Chen, Q. Shi, L. Jiang, C. Wu, W. Zou, Y. Chen
et al., “Arhgap30 promotes p53 acetylation and function in colorectal cancer,” Nature
communications, vol. 5, p. 4735, 2014.
[65] S.-M. Ong, Y.-C. Tan, O. Beretta, D. Jiang, W.-H. Yeap, J. J. Tai, W.-C. Wong, H. Yang,
H. Schwarz, K.-H. Lim et al., “Macrophages in human colorectal cancer are pro-
inflammatory and prime t cells towards an anti-tumour type-1 inflammatory response,”
European journal of immunology, vol. 42, no. 1, pp. 89–100, 2012.
[66] Q. Yan, V. N. Malashkevich, A. Fedorov, E. Fedorov, E. Cao, J. W. Lary, J. L. Cole,
S. G. Nathenson, and S. C. Almo, “Structure of cd84 provides insight into slam family
function,” Proceedings of the National Academy of Sciences, vol. 104, no. 25, pp. 10 583–
10 588, 2007.
[67] N. Hattori, E. Okochi-Takada, M. Kikuyama, M. Wakabayashi, S. Yamashita, and
T. Ushijima, “Methylation silencing of angiopoietin-like 4 in rat and human mammary
carcinomas,” Cancer science, vol. 102, no. 7, pp. 1337–1343, 2011.
[68] K. S. Boles, W. Barchet, T. Diacovo, M. Cella, and M. Colonna, “The tumor suppressor
tslc1/necl-2 triggers nk-cell and cd8+ t-cell responses through the cell-surface receptor
crtam,” Blood, vol. 106, no. 3, pp. 779–786, 2005.
[69] M. Hu, K. Li, N. Maskey, Z. Xu, F. Yu, C. Peng, Y. Li, and G. Yang, “Overexpression
of the chemokine receptor cxcr3 and its correlation with favorable prognosis in gastric
cancer,” Human pathology, vol. 46, no. 12, pp. 1872–1880, 2015.
[70] J. A. Juno, D. van Bockel, S. J. Kent, A. D. Kelleher, J. J. Zaunders, and C. Munier,
“Cytotoxic cd4 t cellsfriend or foe during viral infection?” Frontiers in immunology,
vol. 8, p. 19, 2017.
[71] D. Coble, D. Fleming, M. Persia, C. Ashwell, M. Rothschild, C. Schmidt, and S. Lamont,
“Rna-seq analysis of broiler liver transcriptome reveals novel responses to heat stress,”
The effects of biotic and abiotic stressors on gene expression in chickens, vol. 94, 2013.
[72] Y. Li, Z. Shen, B. Wang, C. Ye, Z. Lai, H. Jiang, Z. Wang, K. Jiang, Y. Ye, and S. Wang,
“Long non-coding rna gpr65-1 is up-regulated in gastric cancer and promotes tumor
growth through the pten-akt-slug signaling pathway,” Cell Cycle, no. just-accepted, pp.
01–20, 2018.
137
[73] S. Ge, X. Xia, C. Ding, B. Zhen, Q. Zhou, J. Feng, J. Yuan, R. Chen, Y. Li, Z. Ge et al.,
“A proteomic landscape of diffuse-type gastric cancer,” Nature communications, vol. 9,
no. 1, p. 1012, 2018.
[74] L. Wang, S. Chen, M. Xue, J. Zhong, X. Wang, L. Gan, E. K. Lam, X. Liu, J. Zhang,
T. Zhou et al., “Homeobox d10 gene, a candidate tumor suppressor, is downregulated
through promoter hypermethylation and associated with gastric carcinogenesis,” Molec-
ular medicine, vol. 18, no. 1, p. 389, 2012.
[75] A. D. Barrow and J. Trowsdale, “The extended human leukocyte receptor complex: di-
verse ways of modulating immune responses,” Immunological reviews, vol. 224, no. 1,
pp. 98–123, 2008.
[76] N. Powell, J. Canavan, T. MacDonald, and G. Lord, “Transcriptional regulation of the
mucosal immune system mediated by t-bet,” Mucosal immunology, vol. 3, no. 6, p. 567,
2010.
[77] J. Parrish-Novak, S. R. Dillon, A. Nelson, A. Hammond, C. Sprecher, J. A. Gross,
J. Johnston, K. Madden, W. Xu, J. West et al., “Interleukin 21 and its receptor are in-
volved in nk cell expansion and regulation of lymphocyte function,” Nature, vol. 408,
no. 6808, p. 57, 2000.
[78] D. J. Birnbaum, P. Finetti, A. Lopresti, M. Gilabert, F. Poizat, O. Turrini, J.-L. Raoul,
J.-R. Delpero, V. Moutardier, D. Birnbaum et al., “Prognostic value of pdl1 expression
in pancreatic cancer,” Oncotarget, vol. 7, no. 44, p. 71198, 2016.
[79] D. Zieker, I. Königsrainer, F. Traub, K. Nieselt, B. Knapp, C. Schillinger, C. Stirnkorb,
F. Fend, H. Northoff, S. Kupka et al., “Pgk1 a potential marker for peritoneal dissem-
ination in gastric cancer,” Cellular Physiology and Biochemistry, vol. 21, no. 5-6, pp.
429–436, 2008.
[80] F. Yao, C. Zhang, W. Du, C. Liu, and Y. Xu, “Identification of gene-expression signatures
and protein markers for breast cancer grading and staging,” PloS one, vol. 10, no. 9, p.
e0138213, 2015.
[81] Y. Kochi, K. Myouzen, R. Yamada, A. Suzuki, T. Kurosaki, Y. Nakamura, and K. Ya-
mamoto, “Fcrl3, an autoimmune susceptibility gene, has inhibitory potential on b-cell
receptor-mediated signaling,” The Journal of Immunology, vol. 183, no. 9, pp. 5502–
5510, 2009.
[82] J. M. Balko, D. B. Johnson, D. Y. Wang, P. Ericsson-Gonzalez, M. Nixon, R. Salgado,
V. Sanchez, D. Schreeder, J. Y. Kim, J. Bordeaux et al., “Mhc-ii expression to drive a
unique pattern of adaptive resistance to antitumor immunity through receptor checkpoint
engagement.” 2018.
[83] Y. Feng, B. Sun, X. Li, L. Zhang, Y. Niu, C. Xiao, L. Ning, Z. Fang, Y. Wang, L. Zhang
et al., “Differentially expressed genes between primary cancer and paired lymph node
metastases predict clinical outcome of node-positive breast cancer patients,” Breast can-
cer research and treatment, vol. 103, no. 3, pp. 319–329, 2007.
138
[84] J. J. O’shea, R. Lahesmaa, G. Vahedi, A. Laurence, and Y. Kanno, “Genomic views of
stat function in cd4+ t helper cell differentiation,” Nature reviews Immunology, vol. 11,
no. 4, p. 239, 2011.
[85] C. G. A. Network et al., “Comprehensive molecular characterization of human colon and
rectal cancer,” Nature, vol. 487, no. 7407, p. 330, 2012.
[86] S.-W. Tong, Y.-X. Yang, H.-D. Hu, X. An, F. Ye, P. Hu, H. Ren, S.-L. Li, and D.-Z.
Zhang, “Proteomic investigation of 5-fluorouracil resistance in a human hepatocellular
carcinoma cell line,” Journal of cellular biochemistry, vol. 113, no. 5, pp. 1671–1680,
2012.
[87] I. Lee, S.-Y. Yeom, S.-J. Lee, W. K. Kang, and C. Park, “A novel senescence-evasion
mechanism involving grap2 and cyclin d interacting protein inactivation by ras associated
with diabetes in cancer cells under doxorubicin treatment,” Cancer research, vol. 70,
no. 11, pp. 4357–4365, 2010.
[88] A. Sukhanova, A. Gorin, I. G. Serebriiskii, L. Gabitova, H. Zheng, D. Restifo, B. L.
Egleston, D. Cunningham, T. Bagnyukova, H. Liu et al., “Targeting c4-demethylating
genes in the cholesterol pathway sensitizes cancer cells to egf receptor inhibitors via
increased egf receptor degradation,” Cancer discovery, vol. 3, no. 1, pp. 96–111, 2013.
[89] S. L’Espérance, M. Bachvarova, B. Tetu, A.-M. Mes-Masson, and D. Bachvarov, “Global
gene expression analysis of early response to chemotherapy treatment in ovarian cancer
spheroids,” BMC genomics, vol. 9, no. 1, p. 99, 2008.
[90] C. J. Liu, J. H. Yang, F. Z. Huang, W. P. Nie, C. P. Liu, X. H. Mao, X. M. Yin, X. B.
Shen, C. Peng, M. F. Chen et al., “Glutathione-s-transferase a 4 (gsta4) suppresses tumor
growth and metastasis of human hepatocellular carcinoma by targeting akt pathway,”
American Journal of Translational Research, vol. 9, no. 2, p. 301, 2017.
[91] X. Wang, R. C. Southard, C. D. Allred, D. R. Talbert, M. E. Wilson, and M. W. Kilgore,
“Maz drives tumor-specific expression of ppar gamma 1 in breast cancer cells,” Breast
cancer research and treatment, vol. 111, no. 1, pp. 103–111, 2008.
[92] Z. Wang, J. Zhu, H. Gu, Y. Yuan, B. Zhang, D. Zhu, J. Zhou, Y. Zhu, and W. Chen, “The
clinical significance of abnormal tim-3 expression on nk cells from patients with gastric
cancer,” Immunological investigations, vol. 44, no. 6, pp. 578–589, 2015.
[93] F. Cruz-Guilloty, M. E. Pipkin, I. M. Djuretic, D. Levanon, J. Lotem, M. G. Lichtenheld,
Y. Groner, and A. Rao, “Runx3 and t-box proteins cooperate to establish the transcrip-
tional program of effector ctls,” Journal of Experimental Medicine, vol. 206, no. 1, pp.
51–59, 2009.
[94] J. Wang, J. W. Fathman, G. Lugo-Villarino, L. Scimone, U. von Andrian, D. M. Dorfman,
and L. H. Glimcher, “Transcription factor t-bet regulates inflammatory arthritis through
its function in dendritic cells,” Journal of Clinical Investigation, vol. 116, no. 2, p. 414,
2006.
139
[95] E. Lozano, N. Joller, Y. Cao, V. K. Kuchroo, and D. A. Hafler, “The cd226/cd155 inter-
action regulates the proinflammatory (th1/th17)/anti-inflammatory (th2) balance in hu-
mans,” The Journal of Immunology, vol. 191, no. 7, pp. 3673–3680, 2013.
[96] M. Andrea, T. Weinschenk, S. Colette, O. Schoor, J. Fritsche, and H. Singh, “Novel pep-
tides and combination of peptides for use in immunotherapy against esophageal cancer
and other cancers,” Feb. 2 2017, uS Patent App. 15/202,388.
[97] A. Mantovani and A. Sica, “Macrophages, innate immunity and cancer: balance, toler-
ance, and diversity,” Current opinion in immunology, vol. 22, no. 2, pp. 231–237, 2010.
[98] Q. Wang, H. Hui, Z. Guo, W. Zhang, Y. Hu, T. He, Y. Tai, P. Peng, and L. Wang, “Adar1
regulates arhgap26 gene expression through rna editing by disrupting mir-30b-3p and
mir-573 binding,” Rna, vol. 19, no. 11, pp. 1525–1536, 2013.
[99] M. Lindstedt, C. A. Borrebaeck, H. Johansson, A.-S. Albrekt, and A. Forreryd, “Analyt-
ical methods and arrays for use in the same,” Oct. 5 2017, uS Patent App. 15/518,580.
[100] C. Dees, I. Schlottmann, R. Funke, A. Distler, K. Palumbo-Zerr, P. Zerr, N.-Y. Lin,
C. Beyer, O. Distler, G. Schett et al., “The wnt antagonists dkk1 and sfrp1 are down-
regulated by promoter hypermethylation in systemic sclerosis,” Annals of the rheumatic
diseases, pp. annrheumdis–2012, 2013.
[101] C.-C. Hong, L. E. Sucheston-Campbell, S. Liu, Q. Hu, S. Yao, K. L. Lunetta, S. A.
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G. D. Bader, and C. Sander, “Pathway commons, a web resource for biological pathway
data,” Nucleic acids research, vol. 39, no. suppl 1, pp. D685–D690, 2010.
[105] D. Warde-Farley, S. L. Donaldson, O. Comes, K. Zuberi, R. Badrawi, P. Chao, M. Franz,
C. Grouios, F. Kazi, C. T. Lopes et al., “The genemania prediction server: biological
network integration for gene prioritization and predicting gene function,” Nucleic acids
research, vol. 38, no. suppl 2, pp. W214–W220, 2010.
[106] C. J. Vaske, S. C. Benz, J. Z. Sanborn, D. Earl, C. Szeto, J. Zhu, D. Haussler, and J. M.
Stuart, “Inference of patient-specific pathway activities from multi-dimensional cancer
genomics data using paradigm,” Bioinformatics, vol. 26, no. 12, pp. i237–i245, 2010.
[107] F. Abbasi, R. Mansouri, F. Gharibdoost, S. Aslani, S. Mostafaei, H. Kavosi, S. Poursani,
140
S. Sobhani, and M. Mahmoudi, “Association study of cd226 and cd247 genes single
nucleotide polymorphisms in iranian patients with systemic sclerosis,” Iranian Journal
of Allergy, Asthma and Immunology, vol. 16, no. 6, p. 471, 2017.
[108] P. Kidd, “Th1/th2 balance: the hypothesis, its limitations, and implications for health and
disease,” Alternative medicine review, vol. 8, no. 3, pp. 223–246, 2003.
[109] S. Yoshino, T. Tabata, S. Hazama, N. Iizuka, K. Yamamoto, M. Hirayama, A. Tangoku,
and M. Oka, “Immunoregulatory effects of the antitumor polysaccharide lentinan on
th1/th2 balance in patients with digestive cancers.” Anticancer research, vol. 20, no. 6C,
pp. 4707–4711, 2000.
[110] O. Finn, “Immuno-oncology: understanding the function and dysfunction of the immune
system in cancer,” Annals of oncology, vol. 23, no. suppl 8, pp. viii6–viii9, 2012.
[111] M. Krohn, M. Listing, G. Tjahjono, A. Reisshauer, E. Peters, B. F. Klapp, and M. Rauch-
fuss, “Depression, mood, stress, and th1/th2 immune balance in primary breast cancer pa-
tients undergoing classical massage therapy,” Supportive Care in Cancer, vol. 19, no. 9,
pp. 1303–1311, 2011.
[112] A. Matsuda, K. Furukawa, H. Takasaki, H. Suzuki, H. Kan, H. Tsuruta, S. Shinji,
and T. Tajiri, “Preoperative oral immune-enhancing nutritional supplementation corrects
th1/th2 imbalance in patients undergoing elective surgery for colorectal cancer,” Diseases
of the colon & rectum, vol. 49, no. 4, pp. 507–516, 2006.
[113] J. B. OConnell, M. A. Maggard, and C. Y. Ko, “Colon cancer survival rates with the
new american joint committee on cancer sixth edition staging,” Journal of the National
Cancer Institute, vol. 96, no. 19, pp. 1420–1425, 2004.
[114] M. Waldner, C. C. Schimanski, and M. F. Neurath, “Colon cancer and the immune sys-
tem: the role of tumor invading t cells,” World journal of gastroenterology: WJG, vol. 12,
no. 45, p. 7233, 2006.
[115] H. Nishikawa and S. Sakaguchi, “Regulatory t cells in cancer immunotherapy,” Current
opinion in immunology, vol. 27, pp. 1–7, 2014.
[116] M. G. Cardenas, E. Oswald, W. Yu, F. Xue, A. D. MacKerell, and A. M. Melnick, “The
expanding role of the bcl6 oncoprotein as a cancer therapeutic target,” Clinical Cancer
Research, vol. 23, no. 4, pp. 885–893, 2017.
[117] H.-J. Park, D.-H. Kim, S.-H. Lim, W.-J. Kim, J. Youn, Y.-S. Choi, and J.-M. Choi, “In-
sights into the role of follicular helper t cells in autoimmunity,” Immune network, vol. 14,
no. 1, pp. 21–29, 2014.
[118] K. Hatzi, J. P. Nance, M. A. Kroenke, M. Bothwell, E. K. Haddad, A. Melnick, and
S. Crotty, “Bcl6 orchestrates tfh cell differentiation via multiple distinct mechanisms,”
Journal of Experimental Medicine, vol. 212, no. 4, pp. 539–553, 2015.
[119] E. Porta-Pardo and A. Godzik, “Mutation drivers of immunological responses to cancer,”
Cancer immunology research, vol. 4, no. 9, pp. 789–798, 2016.
141
[120] H. Stehr, S.-H. J. Jang, J. M. Duarte, C. Wierling, H. Lehrach, M. Lappe, and B. M.
Lange, “The structural impact of cancer-associated missense mutations in oncogenes and
tumor suppressors,” Molecular cancer, vol. 10, no. 1, p. 54, 2011.
[121] Y. Duchartre, Y.-M. Kim, and M. Kahn, “The wnt signaling pathway in cancer,” Critical
reviews in oncology/hematology, vol. 99, pp. 141–149, 2016.
[122] J. L. Stamos and W. I. Weis, “The β -catenin destruction complex,” Cold Spring Harbor
perspectives in biology, vol. 5, no. 1, p. a007898, 2013.
[123] N. E. Hynes and G. MacDonald, “Erbb receptors and signaling pathways in cancer,”
Current opinion in cell biology, vol. 21, no. 2, pp. 177–184, 2009.
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